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ABSTRACT
The goal of this thesis was to advance an implantable drug delivery MEMS
(MicroElectroMechanical Systems) device developed in our laboratory. This device was
designed to locally deliver multiple substances in complex release profiles in order to
maximize the effectiveness of drug therapies. It consists of an array of microreservoirs
etched into a silicon substrate. Different types and dosages of drugs can be contained in
these reservoirs capped by thin gold membranes. The drug release is achieved by the
application of a small anodic potential on the gold membrane in a chloride containing
medium (such as the body fluid). The gold membrane will corrode and disintegrate so
that the drug contained within the reservoir is free to diffuse into the surrounding
medium. Previous researchers have demonstrated in vitro and in vivo release of tracer
molecules as well as a radiolabled chemotherapeutic agent (carmustine, or BCNU) from
the device. However, systematic characterization of the mechanical and electrochemical
behavior of gold membranes on the drug delivery device was necessary in order to
achieve more reliable device performance and to demonstrate efficacy of BCNU
delivered from the MEMS device against an experimental tumor model.
A bulge test apparatus was constructed to characterize the mechanical properties
of gold membranes. Uniform pressure was applied from underneath the gold membrane
and the membrane deflection was measured using optical interferometry. Analyzing the
deflection and pressure data allowed extraction of the elastic modulus and residual stress
of the gold membrane. Gold membranes with in-plane sizes ranging from 20 to 200pim
showed lower modulus (126-168 GPa) than bulk (111) single crystal gold (189 GPa).
But their yield strength (317-351 MPa) was higher than the bulk value.
An in situ experimental setup was constructed to observe the electrochemical
disintegration process of the gold membranes. Real time images recorded from a CCD
camera showed non-uniform corrosion occurring first around the membrane edges.
Bulge tests on the corroded membranes indicated a gradual loss of mechanical integrity
of the gold membranes due to corrosion. The gold membrane disintegration probably
occurred by a combination of membrane thinning through active dissolution and
accumulation of plastic deformation due to the transient formation of a passive film on
top of the gold membrane in each voltammetry cycle.
Dense gold membranes with reproducible opening behavior are critical to the
success of large scale in vivo studies and future commercial applications. Defects in the
gold membranes led to premature leakage of BCNU, a small molecule drug. Wafers with
sputtered gold membranes patterned by wet etching had a higher device yield and
membrane quality than wafers with evaporated gold membranes patterned by lift off. The
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mechanical and electrochemical studies provided guidance to improve the operation
reliability and reproducibility of the drug delivery device.
In vivo release of BCNU from the drug delivery device was demonstrated in a rat
flank model. Acute temporal release kinetics of 14C labeled BCNU in vivo was evaluated
by analysis of the plasma 14C concentration using the accelerator mass spectrometry
(AMS) technique. The in vivo 14C labeled BCNU release profile from the activated
devices was similar to that of the in vitro and subcutaneously injected controls. The time
to reach a steady-state plasma 14C concentration was on the order of one hour.
Efficacy of BCNU delivered from the drug delivery device was demonstrated in a
9L rat flank tumor model. Co-formulation of PEG with BCNU led to complete and rapid
release of payload in vivo. The retarding effect of BCNU on the tumor growth was dose
dependent in the range of 0.67 - 2 mg. BCNU delivered from activated devices seemed
to be as effective as equipotent injections of BCNU against the tumor growth. This tumor
effect study provided preliminary efficacy validation of the drug delivery device as well
as important dosage information for further efficacy evaluation of the BCNU/IL-2
combination therapy.
Thesis Supervisor: Michael J. Cima
Title: Sumitomo Electric Industries Professor of Engineering
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1 Introduction
1.1 Overview of electronic medical implants
The medical implant is defined by the U.S. Food and Drug Administration (FDA)
to be "a device that is placed into a surgically or naturally formed cavity of the human
body if it is intended to remain there for a period of 30 days or more"[21 CFR 812.3(d)].
Development of medical implants that incorporate electronic components, or electronic
medical implants (EMI), began with the invention of the artificial cardiac pacemaker by
Hyman in 19321, followed by the first implantation of the complete pacemaker in a
Swedish patient in 19582. Since then the industry has expanded to include a variety of
implantable electronic devices to address different clinical indications, with an even
larger demand for EMI products in the current decade due to ageing demographic trends
and changing patient care strategies. The global EMI market was estimated to be $9.5
billion in 2003, which is projected to grow to $11.9 billion in 2004 and $32.3 billion in
20093.
A cardiac pacemaker is essentially a pulse generator that delivers electric signals
to the heart to restore its regular rhythm in a patient usually with an abnormally slow
heartbeat. Technological advances over the past 40 years have transformed the early
bulky, single-chamber, fixed rate pacemakers to small, multiprogrammable, dual
chamber, rate adaptive devices with diagnostic functions4 -7. Of particular importance is
the implantable cardioverter-defibrillator (ICD), which has been clinically established as
an effective method for use both in primary prevention of life-threatening events and in
secondary prevention of potentially fatal arrhythmia or cardiac arrest in patients with
coronary disease8 ' 9
Today's EMI industry has spun into a wide array of life improving and life saving
products. Neurostimulators are the descendants of the cardiac pacemaker and have been
developed to restore posture and movement loss or bladder control function due to spinal
cord injury 1'0 '3. They have also been used in deep brain stimulation for treatment of
Parkinson's disease, and in vagus nerve stimulation for control of epilepsy 14 . The
cochlear implant has enjoyed remarkable success over the past 10 years to restore hearing
loss to profoundly deaf people by electrical stimulation of the auditory nerve ' 16
17
Ongoing studies by different research groups are aiming at development of electronic
retina implants to restore sight to millions of people around the world who suffer from
degenerative eye diseases 7 ' 18
Applications descrbied above utilize electric signals to stimulate the cardiac and
nervous systems of the body. Another area that is gaining more and more research and
commercial interests is the use of EMI devices for drug delivery. Implantable drug
infusion pumps are one example of such devices that have already been commercially
available for pain managements9 . A number of electronic drug delivery implants are
currently in various research and development satges, most of which capitalize on the
strength of the microfabrication technology to enhance the capability and impact of drug
delivery, as discussed below.
1.2 Microfabricated devices and systems for drug delivery
Microelectromechanical systems (MEMS) refer to the components or devices
with minimum feature sizes on the order of micrometer range and with some level of
integration between electronic and non-electronic function. Microfabrication, the
technology to fabricate MEMS devices, uses a sequence of process steps (a process flow)
- some borrowed from the integrated circuit (IC) and some developed specifically for
MEMS - to create miniaturized objects2 0' 21. The diverse and flexible nature of MEMS
technology promises a potentially wider range of applications than the IC field. The early
stage of MEMS research and development were dominated by mechanical applications.
Pressure sensors and airbag accelerometers in the automotive industry are two successful
examples. The past several years have seen a rapid expansion of the MEMS field to
biotechnology, environmental monitoring, industrial automation, IT and
telecommunications, with the emergence of new commercial products such as Texas
Instruments' Digital Micromirror Device and the I-STAT Point-of-Care blood analysis
system.
Drug delivery remains a challenge in medicine although numerous polymer-based
controlled drug delivery systems exist today22' 23. Most controlled release implants are
capable of delivering only a single compound at a constant rate although it is well known
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that the rate of a drug's delivery and its interactions with other chemicals have a
significant influence on its effectiveness"'. The digital capabilities and short response
times of MEMS make them attractive for delivering pulses of endocrine hormones, which
is difficult to achieve using the polymer implants2 5. Furthermore, the microfabrication
technology is applicable to a wide variety of materials ranging from traditional silicon
and glass to polymeric materials such as silicone rubber, polycarbonate, isoborny].
acrylate and polyimide 26 . This allows the fabrication of novel drug delivery systems that
integrate both hard and soft materials in order to achieve closed-loop self regulated
delivery of drugs27. For example, hydrogels (a polymer that swells and deswells in
response to changes in external environment such as temperature, pH, glucose level) and
a polydimethylsiloxane (PDMS, also known as silicone rubber) membrane have been
integrated into a silicon substrate to form a glucose sensitive microvalve that can be used
for closed loop insulin delivery28 . A more complex system that integrates a biosensor,
batteries, and electroactive polymer for self regulating responsive delivery of insulin in
vivo, is also being pursued by ChipRx29.
A variety of microfabricated devices and components have been designed to
release drugs of different dosages and with different delivery pattern and duration to
address various clinical needs. Some recent review articles provide useful perspectives
with comparison and contrast on their respective characteristics303 5
This thesis is focused on one microfabricated drug deliver device developed in
this laboratory36, as shown schematically in Figure 1.1. The device is based on a silicon
substrate into which an array of reservoirs is etched. Each reservoir contains a single
dose of drug and is covered with a gold membrane. The drug release is achieved by the
application of a small anodic potential on the gold membrane in a chloride containing
medium (such as the body fluid). The gold membrane will corrode and disintegrate so
that the drug contained within the reservoir is free to diffuse into the surrounding
medium.
19
Drug Anode
Figure 1.1 Schematic of the prototype drug delivery MEMS device developed in this
laboratory 36
.
Advantages of this drug delivery device over other existing devices include the
variety of deliverable compounds, capability of complex release profiles, precise dosing,
absence of moving parts, small size, and quick response time. Limitations include the
small size of the microreservoirs and the need for surgical implantation and explantation.
This kind of device may be particularly useful for the delivery of hormones, powerful
painkillers, chemotherapeutic drugs, and other potent drugs. Besides delivering drugs,
this device may also find potential applications in other fields such as medical
diagnostics, chemical detection, industrial monitoring and control, combinational
chemistry, microbiology, and fragrance delivery3
The initial successful demonstration of proof-of-principle release of single and
multiple substances from a 17 mm square prototype device has stimulated research
interest to further develop this technology. A new generation device was designed that
uses the same electrochemical activation mechanism to achieve drug release but has a
more compact design with 34 reservoirs on a 5 mm square device 38, as shown in Figure
1.2. This is also the device used throughout the study in this thesis.
Figure 1.2 Photograph showing top and bottom of a drug delivery MEMS device used in this
thesis. Photo taken by Rebecca Shawgo.
An important development has been the biocompatibility evaluation of the
materials and voltammetry profiles for this drug delivery device in collaboration with Dr.
James Anderson's group at Case Western Reserve University. All the materials used on
this device were shown to be biocompatible 39. The voltage application with activations
up to five times and gold dissolution were found to induce an acute inflammatory
response equivalent in magnitude to the initial implantation that was resolved within 72
hours40, 4 1. Further exploration of this drug delivery technology has led to development of
a resorbable polymer based drug delivery device 42 and an impedance-based sensor for
non-invasive real-time monitoring of drug release 43
The first in vivo operation of the drug delivery device was demonstrated by the
subcutaneous release of fluorescein dye in a rat flank model performed in collaboration
with Dr. Henry Brem's group at Johns Hopkins Medical Institutions38 (JHMI). The
tissue section fluorimetry profiles shown in Figure 1.3 clearly demonstrate the superior
capability of this MEMS device for achieving localized delivery.
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Figure 1.3 Spatial release profiles of fluorescent dye measured using spectrophotometry in tissue
sections. Solid circles indicate data from the ipsilateral flank, and the open squares indicate data
from the contralateral flank. Animals had (a) an activated device with 8 opened membranes, and
(b) subcutaneously injected dye. Work completed by Rebecca Shawgo38 .
Local delivery is particularly important for many potent drugs that can cause
serious side effects when delivered systemically at high concentration. One example of
such drugs is BCNU, or carmustine, a chemotherapeutic drug. Its low molecular weight
and high lipid solubility allows BCNU to easily cross the blood brain barrier and to be
used for treatment of brain tumors44. Clinical use of BCNU is dose limited because high
systemic concentration of BCNU causes extreme side effects affecting the liver, kidneys,
and spleen4 5. Besides, BCNU has a short half-life both in plasma and within the brain
when administered intravenously46 . Biodegradable polymer wafers containing BCNU
(Gliadel®) have been developed and approved by FDA for treatment of recurrent
malignant glioma 47. Local delivery of BCNU combined with other chemotherapeutic
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agents, such as 0 6 -benzylguanine (0 6 -BG), or immunotherapeutic agents, such as
interleukin-2 (IL-2), can enhance the efficacy of BCNU therapy. Laboratory studies have
indeed demonstrated improved survival on experimental tumor models48' 49. Effective
delivery of the mutli-drug combination requires precise control of the temporal profiles of
the agents, which is generally difficult to achieve using biodegradable polymers. The
MEMS drug delivery device, on the other hand, will enable release of multiple
compounds in complex release profiles to maintain drug concentrations within their
therapeutic window. Therefore, the 06-BG/BCNU or IL-2/BCNU combination therapy
provides a suitable experimental paradigm for evaluating the efficacy of the drug delivery
MEMS device.
Release of radiolabeled BCNU from the drug delivery device has been
demonstrated in vivo3 8. However, the drug leakage problem and limitation of the
radioactivity detection method made it difficult to extract accurate kinetics information of
BCNU release in vivo and to further demonstrate efficacy of BCNU release in a flank
tumor model. On the other hand, the gold membrane is the key functional component on
this drug delivery device. Little was known about its mechanical properties, although it
was realized that characterizing the mechanical integrity of the gold membranes was
important for achieving robust and reliable performance of this MEMS device both in
vitro and in vivo.
1.3 Thesis objectives
This thesis is focused on two aspects of study with different approaches. One is
the characterization of the mechanical and electrochemical properties of the gold
membranes using the materials science approach (processing-structure-properties). The
other aspect of study, evaluation of the operation of the drug delivery device in vivo, will
be performed in collaboration with Dr. Henry Brem's group at JHMI due to the
multidisciplinary nature of the animal studies. However, these two aspects of study do
not completely exclude one another since success of the device in vivo operation
critically hinges on obtaining high quality gold membranes based on the mechanical and
electrochemical characterization results. These two aspects of study will be implemented
with the following specific objectives:
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(1) To characterize the mechanical properties of gold membranes under different
processing conditions (Chapter 2).
(2) To study the electrochemical disintegration process of gold membranes in
chloride containing solutions (Chapter 3).
(3) To evaluate the BCNU release in vitro and to determine the influence of drug
formulation and packaging method on the BCNU release kinetics (Chapter 4).
(4) To evaluate the release kinetics of 14C labeled BCNU from the drug delivery
device in vivo (Chapter 5).
(5) To demonstrate efficacy of BCNU released from the drug delivery device
against the growth of an experimental tumor model (Chapter 6).
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2 Mechanical testing on gold membranes
2.1 Introduction and motivation
Like any other MEMS devices, this drug delivery device must have enough
mechanical stability to ensure robust and reliable performance. Knowing the mechanical
properties of the materials involved is therefore important. Specifically, the mechanical
integrity of the gold membranes is critically important for the proper function of the
device. The gold membranes need to be strong to survive the chemical filling, packaging
and surgical implantation. Moreover, the drug release from the device depends on the
gold membrane disintegration upon the application of voltage, which includes both
mechanical and electrochemical components, as will be discussed in detail in Chapter 3.
It is therefore desirable to characterize the mechanical properties of gold membranes on
this drug delivery device and to understand these properties are affected by different
processing conditions.
The gold membrane on the drug delivery device is essentially a free standing thin
film. There has been long-lasting research interest in the mechanical properties of thin
films motivated not only by purely scientific curiosities, but more importantly by their
application in a wide variety of microelectronic and MEMS devices and systems.
Although in many cases thin films are selected mainly for their electronic, magnetic, or
optical characteristics, understanding their mechanical properties is equally important'. In
order for the devices to function reliably, they must have structural integrity to withstand
the mechanical and chemical forces that arise in their applications. The trend towards
miniaturization and integration in MEMS requires decreases in film thickness and
increases in number of layers. This poses thermal and mechanical compatibility problems
and necessitates a good understanding of the mechanical properties of the thin film
materials.
This chapter first briefly reviews literature on the mechanical testing of free
standing thin films. The bulge test, a well established mechanical testing method, was
used in our study to measure the mechanical properties of the gold membranes on this
drug delivery device and to study their dependence on the film in-plane size and
processing conditions.
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2.2 Review of mechanical testing on free standing thin films
It is known that the physical properties of thin films are often different from those
of their bulk counterparts. One reason is due to the larger surface to volume ratio in thin
films, leading to a larger role of surfaces and interfaces in governing materials
properties2 . For example, the often-observed enhanced yield strength in thin films is
related to the more constrained dislocation motion. Furthermore, thin film preparation
techniques, such as evaporation, sputtering, chemical vapor deposition, sol-gel, etc, are
quite different from those used for bulk materials, such as molding, sintering and casting.
The microstructures of thin films are often far from non-equilibrium and are highly
dependent on the deposition and post-processing methods, which leads to a further
divergence in materials properties.
Measuring the mechanical properties of bulk materials is usually straightforward
and there are standards (such as the ASTM standards) specifying the methods and the
specimen dimensions for measuring the property of interest. This is however not possible
for thin film materials in MEMS. Many new methods have been developed applicable to
the micron scale materials testing. Table 2.1 lists some commonly used techniques in
measuring the mechanical properties of free standing thin films.
Table 2.1 Techniques for measuring mechanical properties of free standing thin films3 6.
Techniques Properties Advantages Disadvantages
measured
Tensile test Elastic and plastic Ease of test data Difficulty in sample
properties, creep, interpretation preparation, sensitivity to
fracture eeffects
Bulge test/ Elastic properties/ Simple test setup, Difficulty in test data
Blister test Plastic properties insensitivity to interpretation
edge effects
Acoustic Elastic properties Measurement of Unable to probe large
method anisotropy in strain phenomenon
elastic constants
The bulge test was chosen for the mechanical testing of the gold membranes on
the drug delivery device because some of the current packaging components can be
readily used to construct the pressurizing unit. One unique feature of our test is that the
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gold membrane is part of the MEMS device so that the test result is directly applicable to
predicting the mechanical behavior of the membrane in actual service. This is different
from any other reported bulge test study where the test structure is non-integrated and the
test is conducted purely for the sake of obtaining the materials properties. On the other
hand, the multiple microfabrication process steps involved in the device fabrication could
cause non-idealities in the gold membrane structure and hence affect its properties, as
will be discussed in the section below.
In the bulge test, uniform pressure is applied from one side of a free standing thin-
film "window", causing it to deflect to the other side (see Fig. 2.1). The stress and strain
in the film can be obtained from measuring the pressure and film deflection. The bulge
test for thin films was first used by Beams in 1958'. After over 30 years of continuous
refinement and modification in film preparation, modeling, testing and data analysis, the
accuracy and reproducibility of the bulge test have been greatly improved. A brief
summary below is helpful for us to correctly conduct the test and interpret the results.
jh
Film
Substrate
Figure 2.1 Schematic showing principle of the bulge test.
(1) Film preparation
Early studies used thin films evaporated on a dissolvable substrate, either a
sodium chloride (NaCl) crystal or a plastic film glued on the end of a copper tube 8. The
main problem with this method is the uncertainty in the film in-plane dimension. The
action of clamping the film over an orifice changed the initial stress state of the film. All
this resulted in large scatter in the measured property data. Use of the silicon bulk
micromachining technique has fundamentally solved the problem of sample preparation.
The anisotropic etching produces perfectly square or rectangular membranes on silicon
substrates that can be readily tested.
(2) Modeling
Modeling of the deformation behavior of the pressurized film is needed to
translate the experimentally determined pressure-deflection relation into the stress-strain
relation to extract the elastic modulus. A spherical bulge was initially assumed, which
was found to be inconsistent with the constraints imposed by the attachment of the film to
the substrates. Later work using energy minimization and/or finite element modeling
gives a generalized form for the bulge test' 6, 9-11
eft MtP = 2 h + c2 4 h3 (Equation 2.1)
a 2 2a
where P is pressure, so is the residual stress, t and a are film thickness and radius, h is the
E
center deflection, v is the Poisson ratio, M is the biaxial elastic modulus, M = , and1-v
E is the Young's modulus. c and c2 are constants dependent on the film geometry, as
listed in Table 2.2.
Table 2.2 Parameters for generalized bulge equation.
Film geometry cl c2 Method
Circular 4 8(1.015 - 0.247v) Numerical approximation
to Hencky's exact solution5
Circular 4 7-v Energy minimization'0
3
Circular 4 2.67 Finite element simulation9
1.026 + 0.233v
Square 3.41 1.981-0.585v Finite element simulations
Square 3.393 1.996-0.613v Energy minimizationI
Long rectangular 2 4 Exact solution, plane strain
3(1 + v) stress state5
For square membranes, the two sets of available constants derived from different
methods are very close. The set of constants derived from the energy minimization
method (c 1=3.393, c2=1.996-0.613v) will be used in our study because it is more recent
than the other set and its applicability has been supported by many experimental
studies12- 14 . Fitting the experimental data with Equation 2.1 allows the extraction of not
only the elastic modulus E (or the biaxial modulus M), but also the residual stress cao in
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the film. Excellent agreement has been reported between the extracted modulus using
Equation 2.1 and that measured using other techniques from independent research
groups.
It should be noted that the derivation of Equation 2.1 is based on the assumption
that the bending stiffness of the membrane can be neglected. This is true for conventional
bulge tests that use thin films with millimeter in plane dimension and submicron
thickness. The importance of bending stiffness is determined by a dimensionless number
(E/o ). (t/a)2 . The bending stiffness can be safely neglected if this number is small (for
example, <10-2). The in plane dimension of the gold membranes on our drug delivery
devices is in the micron scale (a 30om ), resulting in a non-negligible bending stiffness
((E/r o ). (t/a)2 10-2 ). A revised bulge equation should be used'l:
-, ( aot I )Et4h 3 (Equation 2.2)P= C1-+C v2)a  h+c 2 (lv)a
where c is the bending stiffness coefficient, c = 4 for square membranes.
Another caution when using the generalized bulge equation is that the residual
stress in the film has to be tensile. The compressive stress causes the film to buckle or
wrinkle. Finite element calculations have shown that the circumferential stress near the
edge of the film remains compressive even under large applied pressure, resulting in
meaningless measurement s. One way to overcome this problem is to deposit the film
onto another film with tensile stress to give a composite structure with positive value of
(Ct)equivalent = E ti (Equation 2.3a)
Here the multilayered film is treated by taking weighted average of the properties
of individual films, therefore
(Mt)equivalent =- E ii (Equation 2.3b)
where i designates the ith layer of the composite structure. The multiplayer can then be
bulge tested and the properties of the material under study can be extracted from the
composite behavior using the known property data of the other layer material'6.
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2.3 Experimental methods
2.3.1 Fabrication of free standing gold thin films
As mentioned in the previous section, one unique feature of our bulge test is that
it is an integrated test performed on a real device rather than on a test structure. Fig. 2.2
shows the process steps to fabricate the drug delivery device, as briefly introduced below.
Unless otherwise noted, all processing steps were performed in the Technology Research
Laboratory (TRL), a Class 100 cleanroom (defined as "less than 100 particles larger than
0.5 microns in each cubic foot of air space") in the Microsystems Technology Laboratory
(MTL) at MIT.
(1) Double-sided polished Si (4) Gold film deposition and
(100) wafer coated with patterning
1nlxr ctrcce n;triglp
(2) Nitride window patterning (5) Oxide passivation layer I -I LZ
on backside by RIE deposition and patterning Si Nitride Au Oxide
(3) KOH etching to form (6) Nitride removal from
reservoirs beneath gold membrane
Figure 2.2 Microfabrication process flow of the drug delivery MEMS device.
(1) A 4", double sided polished Si wafer (Wafernet Inc., San Jose, CA) was
deposited with 2000 A silicon nitride films on both sides in a vertical tube reactor (VTR -
SVG/Thermco 7000 Series, San Jose, CA) by staff, with the following processing
parameters: 250 seem Dichlorosilane (SiH 2CI2) and 25 seem Ammonia (NH 3), 250 mTorr
pressure and 7750 C. This gave a non-stoichiometric silicon rich nitride film nearly stress
free and with a refractive index of 2.25. Low stress nitride is desirable in that relatively
IV** JL1~~J II1L11~L~
--
thick films can be deposited and patterned without delamination or cracking. It also acts
as a good mask against potassium hydroxide (KOH) etching with negligible etching rate.
The absence of pin holes in the low stress nitride greatly decreased the chance of forming
etch pits in deep and long KOH etching, thus retaining the wafer integrity and increasing
the device yield.
(2) The nitride on one side of the Si wafer was patterned to define the large
opening (480 x 480 gm) of the microreservoirs. Positive photoresist (OCG 825, Arch
Chemicals, Norwalk, CT) was spin coated on the wafer, soft baked at 90 C for 30
minutes, patterned on a mask aligner (EV 620, EV Group Inc., Tempe, AZ) under
365-405 nm UV exposure system, developed in OCG 934 1:1 developer, and hard baked
at 120 C for 30 minutes. The exposed nitride was removed by reactive ion etching
(PlasmaQuest Series 11 Reactor Model 145), using the following recipe: 15 sccm
Tetrafluormethane (CF 4), 15 sccm Helium (He) and 2 sccm Oxygen (02), 20 mtorr
process pressure, 100 W electron cyclotron resonance (ECR) microwave power, 20 W
Radio Frequency (RF) power, and 25 C chamber temperature. The nitride etching rate
was monitored by optical interferometry on NanoSpec (Nanometrics, Inc., Milpitas, CA).
Non-uniform etching was observed across the 4" wafer with the center usually etching
faster than the corners by 0.02-0.15 A/sec.
(3) The wafer was then soaked in a KOH bath (20% by weight) at 85C. It is
well known that the etching of Si in KOH is highly anisotropic and the etch rate of (100)
and (110) crystal planes can be two orders of magnitude higher than that of the (111)
plane. As a result, square pyramidal shaped reservoirs were formed after the KOH
etching. The Si etching rate was about ljlm/min in our process. The etching greatly
slowed down (about 0.5 A/min) upon reaching the nitride on the other side of the wafer.
This allows accommodation of the thickness non-uniformity across the entire wafer. The
resulting small opening of the reservoirs had dimension around 50 x 50 gm. The wafers
after KOH etching must be thoroughly cleaned to remove the K + contamination before
any further process in TRL. The post-KOH cleaning included a 10-minute piranha
etching (a mixture of sulfuric acid and hydrogen peroxide at 3:1 volume ratio), rinse,
another 10-minute piranha etching, spin rinse dry, and 1-minute dip in hydrofluoric acid
(HF) diluted in deionized H 20 (at 1: 50 volume ratio).
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(4) The gold film was then deposited and electrodes patterned on the other side
of the wafer. Two physical vapor deposition methods, evaporation and sputtering, were
used to deposit the gold film. The corresponding gold electrode patterning method was
also different:
A process called lift-off was used to pattern the evaporated gold film. An image
reversal photoresist (AZ 5214E, Clariant) was first spin coated onto the surface of the
wafer having the nitride film covering the reservoirs, soft baked at 90 °C for 30 minutes,
exposed under EV 620 mask aligner, hard baked at 105 °C for 30 minutes, flood exposed
without a mask for 1 minute, and developed in developer (AZ 422 MIF, Clariant). The
patterned wafer was then placed in an electron beam evaporator (Temescal
Semiconductor Products Model VES 2550, Fairfield, CA) for the gold film deposition.
The chamber was pumped down to a vacuum of about 7x 10-7 torr, followed by deposition
of 100 A thick titanium (Ti) layer to promote the adhesion of the gold film to the silicon
nitride. A 3000 A thick gold film was then deposited on top of the Ti layer. Both the Ti
and Au films were deposited at a rate of I A/sec. The wafer was then soaked in acetone
for about half an hour to "lift off' the metals deposited on top of the photoresist, leaving
the areas where the metal films were deposited directly onto the nitride (the electrode
pattern and bond pads) intact.
The gold film on some wafers was deposited using sputtering by an outside
vendor (Lance Goddard Associates, Foster City, CA) in a Class 100 cleanroom. An MRC
903 sputter system was used that utilized a linear scan underneath fixed sputtering
targets. The system was pumped to 2.5 - 4 x 10-7 torr. Ar was bled in to 10 mtorr
pressure to sputter clean the wafer surface for 30 seconds at 0.5 W/cm2 power. A 100 A
thick chromium (Cr) film was immediately sputter deposited as adhesion layer at 0.67
kW DC and a scan rate of about 30 in/min, followed by deposition of 3000 A thick gold
film at 2.5 kW DC with a scan rate of about 8 in/min. The wafer was at room
temperature at the beginning of the sputtering process with the main heating coming from
bombardment of the surface by the depositing Au atoms, and the wafer temperature did
not exceed 90 °C throughout the process. Positive photoresist (OCG 825) was spin coated
onto the wafer surface with the gold film, soft baked at 90 °C for 30 minutes, patterned
on the EV 620 mask aligner, developed and hard baked at 120 °C for 30 minutes. The
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exposed gold areas were removed by wet etching in an iodine-based gold etchant (TFA,
Transene Company Inc., Danvers, MA) at about 28 A/second etching rate. The wafer was
then dipped in a Cr etchant (CR-7, Cyantek Inc., Fremont, CA) briefly (approximately 10
seconds) to etch the exposed Cr. The different gold film deposition conditions led to
different film microstructure, which could affect its properties, as discussed in Section
2.4.2.
(5) A 6000 A thick silicon dioxide (SiO 2) layer was deposited on top of the gold
layer to passivate some portions of the gold electrode (trace). Key requirements for the
SiO 2 are good adhesion to the gold, and in vivo stability and biocompatibility. The
deposition technique of SiO 2 is also limited to low temperature processing (< 350 oC)
since high temperature can lead to thermal grooving and void formation in gold films, as
reported in literature"7 ' 18 as well as shown in our own test (see Figure 2.3). These defects
can cause premature leakage of the drugs contained in the microreservoirs and affect the
device operation reliability.
(a) (b)
(c) (d)
Figure 2.3 Optical micrographs of evaporated gold films. (a) as-deposited, and annealed at (b)
3000 C/4h, (c) 300°C/8h, (d) 350°C/lh. Scale bar is 100 gm.
Plasma enhanced chemical vapor deposition (PECVD) at 3000 C was chosen for
the oxide deposition either on a dual chamber PECVD/RIE system (700 Series,
PlasmaTherm Inc., Kresson, NJ) or by an outside vendor (Strataglass, Mountain View,
CA). The PlasmaTherm system is located in the Exploratory Materials Laboratory
(EML), which is a low level cleanroom without tight control of the particulate count in
the environment. Wafers processed in EML were not allowed to return to the TRL. The
subsequent oxide patterning and nitride etching had to be processed in EML, which could
negatively affect the device yield. The oxide deposition by Strataglass, on the other hand,
was performed in a Class 100 cleanroom. Therefore, wafers could continue to be
processed in TRL after the oxide deposition.
Prior to the oxide deposition on the PlasmaTherm, a 100 A Ti was evaporated on
top of the gold layer and patterned to promote the adhesion between the gold and oxide.
The processing parameters for the oxide deposition were: 600 sccm Silane (SiH4, 5%
diluted in He) and 250 sccm Nitrous Oxide (N 20), 500 mtorr pressure, 25 V DC
controlled RF, and 300 C chamber temperature. Positive photoresist (OCG 825) was
spin coated onto the wafer surface with the oxide layer, soft baked at 90 C for 30
minutes, patterned on a contact mask aligner (Karl Suss MJB-3, Suss MicroTec Inc.,
Waterbury Center, VT), developed and hard baked at 120 C for 30 minutes. The
exposed oxide was removed by RIE on the PlasmaTherm using the following recipe: 20
sccm CF 4 and 5 sccm 02, 20 mtorr pressure, 300 V DC controlled RF, and 25 °C
chamber temperature. Wafers with oxide deposited by Strataglass were patterned in TRL
on the EV 620 mask aligner. The exposed oxide was removed by RIE on the
PlasmaQuest using the following recipe: 15 sccm CF 4, 15 sccm He, 20 mtorr process
pressure, 100 W ECR microwave power, 10 W RF power, and 25 C chamber
temperature.
The PlasmaTherm oxide had a refractive index of 1.47, which is slightly different
from that deposited by Strataglass (1.55). Nevertheless, both types of oxide films
exhibited excellent adhesion to the gold electrode in the Scotch tape test. The Scotch
adhesive tape was applied to the device over the oxide dielectric layer and then peeled
off. No lift-off of the oxide or gold was observed. Moreover, after in vitro activation of
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the devices in the phosphate buffered saline (PBS) solution, no sign of corrosion was
observed on the traces under the microscope.
(6) The last microfabrication step was to remove the silicon nitride beneath the
gold electrode membranes using RIE on the PlasmaTherm (for wafers with the oxide
deposited on PlasmaTherm) or on the PlasmaQuest (for wafers with the oxide deposited
by Strataglass). The wafer was first diced into 5 x 5 mm individual devices on a diesaw
(DAD-2H/6T, Disco Hi-Tec America, Inc., Santa Clara, CA). A 1 m thick positive
photoresist layer was spin coated onto the wafer surface to protect the gold membranes
from the cooling water jet. Devices were cleaned in nanostrip (Cyantek Inc., Fremont,
CA) and placed on top of a 4" test wafer in groups of 20 or less. The electrode side of the
devices was in contact with the test wafer to expose the nitride membranes to the plasma.
The nitride etching recipe on the PlasmaTherm was: 45 sccm Trifluoromethane (CHF3), 5
sccm 02, 300 V DC controlled RF, 30 mtorr pressure, and 25 C chamber temperature.
The same nitride etching recipe in Step (2) was used to etch the nitride on the
PlasmaQuest. However, much longer time (2-2.5 times that needed to etch the same
thickness on a test wafer) was used to completely remove the nitride at the bottom of the
reservoirs due to transport limitations within the confined space. The difficulty to
measure the nitride etching rate in the reservoir made it difficult to evaluate this backside
etching process and know whether the nitride had been completely removed using
conventional methods. The bulge test has been shown to be an effective non-destructive
method to evaluate this nitride etching process, as discussed in Section 2.4.3.
Free standing gold films with different in-plane sizes can be obtained by changing
the nitride window size in Step (2). Unless otherwise noted, Step (5) was omitted when
fabricating the devices bulge tested in this chapter. The absence of oxide from these
devices simplified the fabrication process and more importantly eliminated possibility of
measurement error under the optical profiler due to the difference in the refractive index
between oxide and gold.
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2.3.2 Bulge test apparatus
The bulge test apparatus is shown in Figure 2.4. Compressed air from a gas tank
was regulated by a mini valve and a relief valve (not shown in the figure) to pressurize
the gold membranes on a device placed on a pressurizing unit (Figure 2.4b). Two
stainless steel frames and a silicone gasket (with a 3 mm hole cut in the center) were
readily used in this unit. The thickness of the bottom frame (450 Pim, MicroPhoto,
Roseville, MI) is slightly smaller than the total thickness of the device (350 Plm) and
gasket (125 [Lm, Advanced Bio-Technologies, Inc., Silverdale, WA) so that the gasket
could be compressed against the device bottom to form a seal by tightening nuts and bolts
(# 000-120, Small Parts Inc., Miami Lakes, FL) using a torque screw driver (Model TT-1,
Cooper Power Tools, Hicksville, OH). A Wyko NT 2000 non-contact optical profiler
(Veeco Instruments Inc., Tucson, AZ) was used to measure the profile of the deflected
membrane.
Top frame
Bottom frame
Device
Rubber gasket
Cu plate
(b)
Figure 2.4 (a) Photograph showing the bulge test apparatus, and (b) Cross section of the
pressurizing unit (not drawn to scale).
There are two measurement techniques for the Wyko profiler: Phase Shifting
Interferometry (PSI) for sub-nanometer resolution measurement of smooth surfaces with
steps less than 160nm, and Vertical Scanning Interferometry (VSI) for measuring rougher
surfaces and steps up to several mm high. The basic interferometric principles are similar
in both techniques: A light beam passes through an interferometer objective to the sample
surface. A beam splitter reflects half of the incident beam to a reference mirror surface.
The beams reflected from the sample and the reference surface recombine at the beam
splitter to form interference fringes (see Figure 2.5). The system scans through focus
(starting above focus) at evenly spaced intervals as the camera captures frames of
interference data. The analysis unit of the system uses advanced computer algorithms to
resolve the surface height profile. One big difference between the VSI and PSI techniques
is that in VSL, the white-light source is not filtered, and the system measures the degree of
fringe modulation, or coherence, instead of the phase of the interference fringes as in the
PSI mode. The VSl mode (with a vertical resolution of 3 nm) was used to measure the
bulged profile of gold membranes in this chapter.
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Figure 2.5 Interferometric principle of the Wyko profiler' 9.
2.3.3 Data analysis
In the bulge test, pressure was gradually applied to the gold membrane from 0 psi,
stopped at every 5 psi (1 psi = 6895 Pa) increment for the profile of the deformed
membranes to be recorded. After reaching 60 psi, the pressure was slowly decreased at 5
or 10 psi interval by careful control of the relief valve. The profile of the depressurized
membranes was also recorded. The profile acquisition and analysis was performed using
Vision 32, a software accessory to the Wyko profiler.
Figure 2.6a shows an example of the raw measurement dataset of a gold
membrane under 60 psi pressure recorded by Vision 32. A terms mask was first defined
that assumed the subregions excluding the electrode and trace to be of the same height
level. This terms mask was then activated to remove the linear tilt from the measurement.
Of the various post-processing options available in Vision 32, the 2D analysis is the most
useful in that the membrane center deflection can be directly obtained (see Figure 2.6b).
All the deflection data in this Chapter were taken from the gold film center relative to a
reference point 200 Cpm away on the trace.
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The 3D interactive plot is another appealing feature of the software, which gives
vivid three-dimensional representation of the deformed gold membranes, as illustrated in
Figure 2.7.
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Figure 2.7 3D plots of a gold membrane (a) with no pressure being applied and (b) under 60 psi
pressure.
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2.3.4 Microstructural characterization
Besides the Wyko profiler, other characterization tools were used to reveal the
microstructural characteristics of the gold membranes, which not only helped to explain
the bulge test results, but also served as useful guidance for the optimization of gold
membrane processing conditions.
The optical microscopy observation was performed on an Olympus microscope
(BH-2). A field emission scanning electron microscope (Hitachi 4700) was used to
observe the in-plane grain structure of the gold membranes. A transparent sheet was
overlaid on the printed SEM image so that the grains could be identified by tracing the
grain boundaries using a marker. The resulting overlay was scanned to form a digital
image, which can then be analyzed using the UTHSCSA ImageTool program (Version
3.0). X-ray diffraction was conducted on a Rigagu D/Max diffractometer using Cu Ks
radiation to obtain the membrane texture information. A Tencor contact surface profiler
(P10, KLA-Tencor, Milpitas, CA) was used to measure the deposited gold film thickness
and to compare with the measurement by the Wyko profiler. The surface morphology of
gold membranes was also observed by atomic force microscopy (AFM) under a
Nanoscope III Multimode AFM system (Veeco Instruments Inc., Tucson, AZ).
2.4 Results and discussion
2.4.1 Evaporated gold membranes
2.4.1.1 Elastic deformation
Figure 2.8 shows the center deflection of two gold membranes in three
pressurizing-depressurizing cycles. As expected, both membranes showed increased
deflection with increasing pressure. Depressurizing led to an almost identical path back to
the initial state. The good coincidence of the deflection data in the three pressurizing-
depressurizing cycles indicated elastic deformation behavior of the two gold membranes
up to 60 psi pressure.
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Figure 2.8 Center deflection of two gold membranes in three pressurizing-depressurizing cycles.
The in-plane sizes of the two membranes measured under the optical microscope were (a) 36.6
Lm and (b) 54.3 Gnm.
A revised equation from Equation 2.2 was used when fitting the experimentally
measured data:
P = P + Plh + P2h3 (Equation 2.4)
The fitting parameter Po was introduced to account for the pressure and deflection
offset errors, which led to a non-zero deflection at zero pressure. The thickness of the
gold membrane was measured by the contact profiler to be 2500 A, which was lower than
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the target value (3000 A). It was later found out that full calibration for the TRL e-beam
equipment was not achieved at the time of film deposition. XRD analysis showed a
strong (111) texture in the evaporated gold film (see Figure 2.9). Therefore, the
calculated Poisson ratio for (111) textured gold (v( 1) = 0.571 3) was used to extract the
residual stress and elastic modulus, as listed in Table 2.3.
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40
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Figure 2.9 XRD spectrum
the gold membranes.
on the drug delivery MEMS device, showing strong (111) texture of
Table 2.3 Bulge test curve fitting and extracted mechanical properties for two gold membranes.
Membrane in-plane size (m) 36.6 54.3
Curve Po 0.65±1.19 -0.26±1.05
fitting PI 7.8 1±3.52 24.06±+2.45
results P2 72.22+3.69 14.50+1.38
R2 0.993 0.992
Biaxial modulus M(GPa) 148 ± 8 143 14
Residual stress o (MPa) 23 ± 10 157 ±16
The coefficients of determination (R 2) for both membranes were very close to 1,
indicating good fitting of the experimental data to the bulge equation. The extracted
modulus for the two membranes was about 23% lower than the theoretical modulus for
(111) single crystal gold (189GPa 2 ). However, similar amount of lowering in modulus
has been reported in other researchers' tests on free standing gold films or other metal
films3 13, 21. It is intuitively obvious that the lowering of the thin film stiffness should be
related with its non-equilibrium microstructure. Some models have been proposed
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attempting to correlate thin film microstructural features such as texture22, voids2 2, grain
boundary compliance23' 24, microcracking22' 2, or dislocation movement2 27, to the
measured lower moduli. However, no consensus explanation has been achieved and the
exact mechanism for the lowered stiffness in thin films remains unclear.
2.4.1.2 Plastic deformation
Figure 2.10 shows the center deflection vs. pressure curves for three gold
membranes with larger in-plane size. The large deviation of the membrane center
deflection between the pressurizing segment and the depressurizing segment indicates
that plastic deformation occurred. Moreover, the membrane with 215.7 pm in-plane size
ruptured before pressure was increased to 30 psi.
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Figure 2.10 Center deflection vs. pressure for three gold membranes with in-plane sizes of (a)
100.9 gm, (b) 127.2 m, and (c) 219.7 pm.
The free standing square film has a non-uniform stress state under the application
of pressure, with biaxial stress state in the film center and plane strain stress state towards
the film edge. If we rewrite Equation 2.1 as:
Pa 2 c 2 h 21
=~clt 2cl 02 o (Equation 2.5)
where c = 3.393, c 2 = 1.966-0.613v for square membranes, we can use Equation 2.5 to
estimate the stress in the membrane under a given pressure:
Pa2
33 = 93 (Equation 2.6)
3.393ht
The gold membrane yield strength ay, therefore, can be obtained by comparing
the stress of the two membranes (with 54.3 pm and 100.9 gtm in-plane sizes respectively)
at 60 psi pressure, and the fracture strength qf estimated using the deflection data of the
219.7 gm membrane under 25 psi pressure:
317 MPa < a < 35 1MPa (Equation 2.7a)
cr 340 MPa (Equation 2.7b)
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The gold membranes on the drug delivery device showed significantly higher
strength than the bulk gold (See Table 2.4). This is not surprising, as similar
strengthening phenomena have been reported not only for the gold thin films, but also for
a number of other thin film systems 28 -32. The non-equilibrium microstructure of thin
films, notably the small grain size and large surface/volume ratio, is generally believed to
be correlated with the enhanced strength in thin films. There have been extensive studies
to investigate the deformation and strengthening behavior of thin films. Many models,
such as grain boundary strengthening, dislocation interaction strengthening, film
thickness and texture effect, have been proposed14 ' 33' 34. A systematic experimental study
on the stress-strain relationship of gold membranes supplemented with careful
microstructural observation and modeling, though beyond the scope of this thesis'
objectives, may be necessary to fully understand the strengthening mechanism. For
example, a long rectangular membrane is more suitable than a square membrane in
studying the stress-strain relationship. The stress state in a long rectangular membrane
approaches that of plane strain1 3, making it straightforward to analyze both elastic and
plastic deformation of the membrane. Change of the testing strain rate and temperature,
and detailed microstructural analysis on the kinetics of dislocation motion, may provide
useful insight into the deformation and strengthening behavior of thin films.
Table 2.4 Mechanical properties of bulk gold20.
Condition Yield strength (MPa) Tensile strength (MPa)
Cast N/A 125
Wrought, annealed N/A 130
Work hardened 205 220
2.4.1.3 Gold/nitride composite membranes
To circumvent the plastic deformation of gold membranes with larger in-plane
sizes, gold/nitride composite membranes were bulge tested. Figure 2.11 shows the
deflection vs. pressure curves for five composite membranes with in-plane sizes ranging
from 25.4 ptm to 215.7 ptm. The presence of the stiff nitride strengthened the gold
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membranes, leading to only elastic deformation behavior up to 60 psi pressure for all the
samples tested.
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Figure 2.11 Center deflection of gold/nitride composite membranes (a) with smaller in-plane size
and (b) with larger in-plane size in a pressurizing-depressurizing cycle.
Equation 2.2 and 2.3 were used to fit the curves in Figure 2.11. The modulus and
Poisson's ratio of nitride were taken to be 250 GPa and 0.23 respectively35. The nitride
thickness after the KOH etching was measured to be 2032 A, and its residual stress was
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measured by wafer curvature to be 180 MPa. The extracted gold membrane properties
from curve fitting results are shown in Table 2.5.
Table 2.5 Mechanical properties of evaporated gold membranes extracted from bulge test
on gold/nitride composite membranes.
Membrane in-plane size (lm) 25.4 47.3 115.9 184 215.7
Biaxial modulus (GPa) 126 145 144 168 146
+108 +48 +29 ±12 +23
Residual stress (MPa) 69 151 152 140 259
+21 +17 +28 ±15 ±43
The extracted gold membrane properties from the gold/nitride composite systems
were comparable to those from pure gold membranes, indicating good applicability of the
bulge test analytical solutions to the gold membranes with much smaller in-plane sizes.
The narrow range of the biaxial modulus suggested that the modulus was probably
independent of the membrane in-plane sizes.
It is also noted that the extracted property data showed relatively larger error than
those from pure gold membranes, especially for composite membranes with smaller in-
plane sizes. This is most probably a result of experimental error in the measurement of
deflection and pressure values, which becomes more significant for films with smaller in-
plane sizes because of the much smaller total deflection of the membrane. Another
contributing factor is the neglect of the very thin Ti adhesion layer (approximately 100 A
thick) between nitride and gold when applying the bulge equation to the composite
membranes mainly due to unavailability of the property data of this Ti layer.
2.4.2 Sputtered gold membranes
Two gold membranes deposited by sputtering were also bulge tested and the
deflection vs. pressure data were plotted in Figure 2.12. Both membranes had relatively
small in-plane sizes, and exhibited only elastic deformation up to 60 psi pressure. Table
2.6 lists the extracted mechanical properties for the two membranes according to
Equation 2.2:
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Figure 2.12 Center deflection of two sputtered gold membranes under one pressurizing-
depressurizing cycle.
Table 2.6 Mechanical properties of sputtered gold membranes extracted from bulge test.
Membrane in-plane size (m) 46.4 39.0
Biaxial modulus (GPa) 157 + 23 149 + 27
Residual stress (MPa) 257 + 11 283 ± 10
The two sputtered membranes showed slightly higher modulus and residual stress
than the evaporated gold membranes with comparable in-plane sizes. Although the result
is not statistically conclusive due to the small difference in the modulus value and limited
number of sputtered samples tested, it is not surprising that gold membranes fabricated
under different processing conditions exhibited differences in the microstructure and
mechanical properties.
Schematics of the evaporation and DC sputter deposition equipments are shown
in Figure 2.13. In evaporation, the source material is heated in a vacuum chamber by
electron beam, giving off evaporated atoms that travel along "line-of-sight" and condense
onto the substrate surface. In contrast, the DC sputter deposition uses a parallel plate
arrangement, with the target placed on the cathode and the substrate on the anode. An
inert gas, such as argon (Ar), is introduced into the chamber at low pressure. A voltage
applied across the two electrodes creates plasma and ionizes Ar, which is accelerated to
the target and dislodge, or sputter the target atoms. These atoms then travel through the
plasma and strike the surface of the substrate to form a film. Although both evaporation
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and sputtering are physical vapor deposition techniques, the difference in the generation
of depositing atoms between these two processes leads to different structural
characteristics of the resulting films, as summarized in Table 2.7.
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Figure 2.13 Schematics of (a) an electron beam evaporator and (b) a DC sputter deposition
equipment. Redrawn after Plummer36.
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Table 2.7 Comparison of evaporation and sputter deposition techniques 37' 38.
Evaporation Sputter deposition
Mechanism of atom Thermal evaporation Ion Bombardment and collisional
removal (hot source) momentum transfer (cool target)
Pressure High-ultrahigh (-10-5 to 10- °0 Low-medium (-1 to 100 mtorr)
torr)
Species energy - 0.1 to 0.2 eV for evaporants 3 to 10 eV for sputtered atoms
Atomic mean free Larger than source-substrate Less than target-substrate spacing
path spacing
In situ cleaning Not an option Easily done with a sputter etch
Adhesion Often poor Excellent
Uniformity Difficult Easy over large areas
Surface damage Very low Ionic bombardment damage
Film purity Better Possibility of incorporating
impurities
Figure 2.14 shows the SEM micrographs of the top surface (perpendicular to the
film thickness direction) of evaporated and sputtered gold films. Both films show cellular
like in-plane grain morphology, and the sputtered film has slightly more rounded grains
(roundness 0.72) than the evaporated film (roundness 0.69). According to Thornton's
zone model39, gold films are expected to exhibit columnar grain structure in the thickness
direction due to the relatively high mobility of gold atoms4 0. Gold has a low hardness and
tends to smear when being polished, making it difficult to obtain good quality SEM cross
section images. Nevertheless, transmission electron microscopy (TEM) and scanning
tunneling microscopy (STM) examinations on gold films deposited using similar
conditions as in our study have confirmed the columnar grain structure' 42.
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Figure 2.14 SEM micrographs of top surface of gold films deposited by (a) evaporation
(thickness 2500 A) and (b) sputtering (thickness 3000 A).
Figure 2.15 shows the image analysis result for the two types of gold films. The
average in-plane grain size for the evaporated gold film is 75 nm (standard deviation 18
nm), comparing to 66 nm (standard deviation 27 nm) for the sputtered gold film. The
sputtered film also showed a wider spread in the 2D grain size distribution. The atoms
that arrive on the sputtered surface are more energetic than those arrive on the evaporated
surface, and hence have higher surface diffusivity. The bombardment of the sputtered
atoms to the substrate surface leads to increase of the surface temperature, which also
helps to enhance the mobility of depositing atoms. All these factors may have contributed
to a denser film by sputtering than by evaporation. Phenomenologically, this result also
seems to agree with one principle in the packing theory, which states that the fraction of
voids in packed particulate materials decreases with increasing width of particle size
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Figure 2.15 In-plane grain size distribution of gold films deposited by (a) evaporation (N=151
grains, thickness 2500 A) and (b) sputtering (N= 180 grains, thickness 3000 A).
Surface morphology comparison of the two types of films by AFM (see Figure
2.16) indicated that both films were very smooth, with the sputtered film having slightly
lower root-mean-square (RMS) roughness (1.80 nm) than the evaporated gold film (2.56
nm). The RMS roughness measured by the Wyko profiler was around 6 nm for both types
of films. The difference could be due to the fact that a much larger area was measured (30
x 30 gm) by the optical profiler than by the AFM (1 x 1 gtm).
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Figure 2.16 AFM surface morphology of gold films deposited by (a) evaporation (thickness
2500 A) and (b) sputtering (thickness 3000 A).
As mentioned in the device fabrication section (2.3.1), gold electrodes deposited
by evaporation were patterned using the lift-off process. The multiples photoresist
processing steps before the gold film deposition increased possibility of contamination by
photoresist residues or other particles on the patterned wafer, even though great care was
taken to minimize contamination in the lithography step and a short (1 minute) oxygen
plasma etching (TRL asher) was also used just before putting the wafer into the e-beam
chamber. The particles could become origin of defects in the gold film, which can lead to
premature leakage of chemicals (especially those of low molecular weight) contained in
the reservoirs. In contrast, a wet etching process was used to pattern the sputtered gold
film. The wafer was thoroughly cleaned in Nanostrip (a mixture of sulfuric acid and
hydrogen peroxide) before it was placed into the sputtering chamber. Besides, a 30-
second Ar ion sputter etching step was performed to further clean the wafer surface just
before the gold film deposition. Wafers with sputtered gold membranes thus had a higher
device yield and better membrane quality than wafers with evaporated gold membranes,
as supported by the leak test that will be discussed in Chapter 4.
2.4.3 Nitride etching evaluation
The bulge test was used to non-destructively evaluate the bottom nitride etching
step in the microfabrication process. Devices used in this study had evaporated gold
membranes. The nitride thickness was 1350 A. Due to an error made by the outside
vendor, about 6000 A was deposited on the bottom of the reservoirs. Therefore, both the
oxide and nitride need to be removed. The nitride etching recipe given in Section 2.3.1
was essentially the oxide etching recipe with oxygen added, and therefore worked for
both nitride and oxide etching. Twenty devices were etched in the PlasmaQuest with the
etching time ranging from 500 to 3600 seconds. All the etching was performed within an
8-hour period.
Figure 2.17 shows the center deflection of gold membranes with different nitride
etching time after bulge tested to 60 psi pressure. The intermediate plateau region seems
to suggest that all the nitride was removed with 1500sec etching. This observation
however was not well-grounded since the membrane center deflection is strongly
dependent on its in-plane size, which was different among the membranes tested. A better
way is to compare the extracted mechanical properties of these membranes assuming
nitride was completely removed. The pressure-deflection data corresponding to different
nitride etching time were fitted using Equation (2.2), and the extracted property data are
listed in Table 2.8.
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Figure 2.17 Center deflection of 11 gold membranes with different nitride etching time.
Table 2.8 Extracted mechanical properties of gold membranes
with different nitride etching time.
Etching time (sec) 1500 2000 2300 2500 2700 3000 3300 3600
Biaxial modulus 175 135 142 142 121 130 103 75
(GPa) ±13 ±9 ±7 ±11 ±6 ±9 ±3 +5
Residual stress 123 152 68 49 139 130 41 61
(MPa) ±11 19 110 115 ±7 ±10 14 +9
It is clearly seen from the modulus values that the nitride was not completely
removed until after 2000 second etching. The plateau in the elastic modulus from 2000 to
3000 seconds suggests that gold is immune to the CF 4/0 2 plasma etching condition
within a certain time range. However, prolonged etching with ion bombardment could
have physically weakened the gold membranes, or even caused local yielding of the
membrane, which led to abrupt drop of the elastic modulus. An obvious increase in the
roughness of the gold membrane bottom surface was also observed with excessive
etching (see Figure 2.18).
(d)
Figure 2.18 Optical micrographs of backside gold membranes (approximately 67 Cpm in-plane
size) with different nitride etching time: (a) unetched, (b) 1000 seconds (c) 2500 seconds and
(d) 3600 seconds. The Nomarski filter was used to enhance the image contrast.
It should be noted that the nitride etching time determined from this study may
not be applicable to other devices even from the same wafer and using the same nitride
etching recipe. The PlasmaQuest is used to perform both PECVD and etching for a
variety of films in the same chamber. The etching rate tends to change with different
chamber processing history. However, the value of this nitride etching study is that it
provided a quick and reliable method to non-destructively evaluate the bottom nitride
etching step, which is especially important given the machine variability.
2.5 Conclusions
The bulge test is a viable technique to test the mechanical properties of the gold
membranes on the drug delivery MEMS device. Important results from experiments
performed in this Chapter are:
(1) Available analytic solutions seem to still work well for membranes with in-
plane size in the range of 20-200 gm. The extracted gold membrane properties from the
gold/nitride composite systems were comparable to those from pure gold membranes.
(2) The biaxial moduli of gold membranes were independent of their in-plane
sizes and were lower compared to bulk (111) gold. The yield strength of the gold
membranes, on the other hand, was significantly higher than the bulk value.
(3) Comparing to evaporated gold membranes, membranes deposited by
sputtering was denser with a wider grain size distribution. The extracted modulus of
sputtered gold membranes was also higher than that of evaporated gold membranes with
similar in-plane sizes.
(4) The bulge test also provided a reliable non-destructive method to evaluate
the bottom nitride etching step in the microfabrication process. The nitride etching test
indicated that gold was immune to the CF4/0 2 plasma only within a certain time range,
and that extended etching tended to weaken the gold membranes and led to decrease of
the membrane modulus.
2.6 Acknowledgements
Prof. Carl Thompson is acknowledged for giving access to the Wyko profiler in
his laboratory. Robert Bernstein and James Serdy helped with the bulge test setup. Lin
Han performed the AFM analysis.
61
2.7 References
1. Nix, W.D. Mechanical properties of thin films. Metallurgical Transactions A:
Physical Metallurgy and Materials Science 20A, 2217-2245 (1989).
2. Alexopoulos, P.S. and O'Sullivan, T.C. Mechanical properties of thin films.
Annual Review of Materials Science 20, 391-420 (1990).
3. Huang, H. Mechanical properties of free-standing polycrystalline metallic thin
films and multilayers, Ph.D. Thesis, Harvard University, 1998.
4. Sharpe, W.N., Jr. and Hemker, K.J. Mechanical testing of free-standing thin films.
Materials Research Society Symposium Proceedings 687, 293-304 (2002).
5. Hohlfelder, R.J. Bulge and blister testing of thin films and their interfaces, Ph.D.
Thesis, Stanford University, 1999.
6. Pan, J.Y. and Senturia, S.D. Suspended-membrane methods for determining the
effects of humidity on the mechanical properties of thin polymer films. Annual
Technical Conference - Society of Plastics Engineers 49th, 1618-1621 (1991).
7. Beams, J.W. Properties of thin films on Au and Ag. Structure and Properties of
Thin Films, Proceedings of an International Conference, 183-192 (1959).
8. Brotzen, F.R. Mechanical testing of thin films. International Materials Reviews
39, 24-45 (1994).
9. Lin, P. and Senturia, S.D. The in-situ measurement of biaxial modulus and
residual stress of multi-layer polymeric thin films. Materials Research Society
Symposium Proceedings 188, 41-46 (1990).
10. Pan, J.Y. A study of suspended-membrane and acoustic techniques for the
determination of the mechanical properties of thin polymer films, Ph.D. Thesis,
Massachusetts Institute of Technology, 1991.
11. Vlassak, J.J. New experimental techniques and analysis methods for the study of
the mechanical properties of materials in small volumes (nanoindentation,
anisotropy, pressure, deflection), Ph.D. Thesis, Stanford University, 1994.
12. Karimi, A., Shojaei, O.R., Kruml, T. and Martin, J.L. Characterization of TiN thin
films using the bulge test and the nanoindentation technique. Thin Solid Films
308-309, 334-339 (1997).
13. Paviot, V.M., Vlassak, J.J. and Nix, W.D. Measuring the mechanical properties of
thin metal films by means of bulge testing of micromachined windows. Materials
Research Society Symposium Proceedings 356, 579-584 (1995).
14. Leung, O.S. Studies in the strengthening mechanisms of thin polycrystalline gold
films, Ph.D. Thesis, 2001.
15. Small, M.K. and Nix, W.D. Analysis of the accuracy of the bulge test in
determining the mechanical properties of thin films. Journal of Materials
Research 7, 1553-1563 (1992).
16. Small, M.K. Use of the bulge test in measuring the mechanical properties of thin
films, Ph.D. Thesis, Stanford University, 1993.
62
17. Jiran, E. and Thompson, C.V. Capillary instabilities in thin films. Journal of
Electronic Materials 19, 1153-1160 (1990).
18. Hummel, R.E., DeHoff, R.T., Matts-Goho, S. and Goho, W.M. Thermal grooving,
thermotransport and electrotransport in doped and undoped thin gold films. Thin
Solid Films 78, 1-14 (1981).
19. Zecchino, M., Novak, E. and Schmit, J. Advances in Optical Profiling Open New
Applications, www.veeco.com/pdf/Optical Library/ Advances in_Optical.pdf.
20. ASM Handbook, Vol. 2: Properties and Selection - Nonferrous Alloys and Pure
Metals. (ASM International, 1990).
21. Kalkman, A.J., Verbruggen, A.H. and Janssen, G.C.A.M. Young's modulus
measurements and grain boundary sliding in free-standing thin metal films.
Applied Physics Letters 78, 2673-2675 (2001).
22. Huang, H. and Spaepen, F. Tensile testing of free-standing Cu, Ag and Al thin
films and Ag/Cu multilayers. Acta Materialia 48, 3261-3269 (2000).
23. Korn, D., Morsch, A., Birringer, R., Arnold, W. and Gleiter, H. Measurements of
the elastic constants, the specific heat, and the entropy of grain boundaries by
means of ultrafine grained materials. Journal de Physique, Colloque, C5-
769/C765-779 (1988).
24. Weller, M., Diehl, J. and Schaefer, H.E. Shear modulus and internal friction in
nanometer-sized polycrystalline palladium. Philosophical Magazine A: Physics of
Condensed Matter: Structure, Defects and Mechanical Properties 63, 527-533
(1991).
25. Laws, N. and Brockenbrough, J.R. The effect of micro-crack systems on the loss
of stiffness of brittle solids. International Journal of Solids and Structures 23,
1247-1268 (1987).
26. Gibeling, J.C. and Nix, W.D. Observations of anelastic backflow following stress
reductions during creep of pure metals. Acta Metallurgica 29, 1769-1784 (198 1).
27. Nix, W.D., Gibeling, J.C. and Hughes, D.A. Time-dependent deformation of
metals. Metallurgical Transactions A: Physical Metallurgy and Materials Science
16A, 2215-2226 (1985).
28. Emery, R.D. and Povirk, G.L. Tensile behavior of free-standing gold films. Part
II. Fine-grained films. Acta Materialia 51, 2079-2087 (2003).
29. Emery, R.D. and Povirk, G.L. Tensile behavior of free-standing gold films. Part I.
Coarse-grained films. Acta Materialia 51, 2067-2078 (2003).
30. Kang, Y.S., Ho, P.S., Knipe, R. and Tregilgas, J. Film thickness effect on tensile
properties and microstructures of submicron aluminum thin films on polyimide.
Materials Research Society Symposium Proceedings 436, 35-40 (1997).
31. Ruud, J.A., Josell, D., Spaepen, F. and Greer, A.L. A new method for tensile
testing of thin films. Journal of Materials Research 8, 112-117 (1993).
32. Yu, D.Y.W. and Spaepen, F. The yield strength of thin copper films on Kapton.
Journal of Applied Physics 95, 2991-2997 (2004).
63
33. Keller, R.M., Baker, S.P. and Arzt, E. Quantitative analysis of strengthening
mechanisms in thin Cu films: effects of film thickness, grain size, and passivation.
Journal of Materials Research 13, 1307-1317 (1998).
34. Zhang, J.-M. and Xu, K.-W. The yield strengths of polycrystalline thin films.
Journal ofAdvanced Materials 34, 51-58 (2002).
35. Sharpe, W.N., Jr. Mechanical properties of MEMS materials. MEMS Handbook,
3/1-3/33 (2002).
36. Plummer, J.D., Deal, M.D. and Griffin, P.B. Silicon VLSI Technology,
Fundamentals, Practice and Modeling. (Prentice Hall, Upper Saddle River, NJ;
2000).
37. Ohring, M. Materials Science of Thin Films, Deposition and Structure., Second
Edition. (Academic Press, San Diego, CA; 2002).
38. Madou, M.J. Fundamentals of Microfabrication, the Science of Miniaturization.,
Second Edition. (CRC Press, Boca Raton, FL; 2002).
39. Thornton, J.A. Structure-zone models of thin films. Proceedings of SPIE-The
International Societyfor Optical Engineering 821, 95-103 (1988).
40. Thompson, C.V. Structure evolution during processing of polycrystalline films.
Annual Review of Materials Science 30, 159-190 (2000).
41. Harris, K.E. and King, A.H. Localized texture formation and its detection in
polycrystalline thin films of gold. Materials Research Society Symposium
Proceedings 317, 425-430 (1994).
42. Munuera, C., Aznarez, J.A., Rodriguez-Canas, E., Oliva, A.I., Aguilar, M. and
Sacedon, J.L. Study of rough growth fronts of evaporated polycrystalline gold
films. Journal of Vacuum Science & Technology, A: Vacuum, Surfaces, and Films
22, 1767-1772 (2004).
43. Forsyth, A.J., Hutton, S.R., Osborne, C.F. and Rhodes, M.J. Effects of
interparticle force on the packing of spherical granular material. Physical Review
Letters 87, 244301/244301-244301/244303 (2001).
64
3 Electrochemical disintegration of gold membranes
3.1 Introduction and motivation
Release of chemicals from the drug delivery MEMS device is achieved by the
electrochemical disintegration of gold membranes upon the application of a potential.
Understanding the gold membrane disintegration mechanism provides useful guidance to
improve the reliability of device operation. For the first prototype drug delivery device
developed by Santini, an extended (several seconds to less than 5 minutes) DC potential
of 1.04 V vs. a saturated calomel electrode (SCE) was applied to activate and remove the
gold membranes in the phosphate buffered saline (PBS) solution. Santini performed in
situ observation of the membrane disintegration and found non-uniform corrosion
occurred across the membrane. He concluded that both corrosion and physical stress
(from sources both inside and outside the reservoir) contributed to the disintegration of
the gold membranes. However, it was unclear whether these two factors acted
independently, or if they acted in combination through the stress corrosion cracking
(SCC) mechanism'.
The DC potential was later found to be less reproducible to activate gold
membranes in the calf serum, a biological medium close to the body fluid. A revised
voltammetry profile was developed by Shawgo to efficiently activate the membranes in
vivo 2. This profile has since been used in both in vitro and in vivo release studies. It is
desirable to understand the gold membrane disintegration mechanism with the new
voltammetry profile as it closely correlates with the reliability of device operation both in
vitro and in vivo.
An in situ experimental setup was constructed to observe the electrochemical
disintegration process of the gold membranes in PBS. Real time images recorded from a
CCD camera attached to an optical microscope were used to trace the microstructural
changes of the gold membranes. The bulge test was again used in this chapter to evaluate
the mechanical integrity of the corroded gold membranes. A qualitative mechanism was
developed based on the visualization and mechanical testing results.
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3.2 Experimental methods
3.2.1 Device fabrication and packaging
Devices were fabricated using the same microfabrication process described in the
previous chapter (Section 2.2.1). The gold membranes on these devices were deposited
by evaporation. A 100 A Ti layer was deposited both before and after the gold film
evaporation to promote the adhesion of gold to the nitride as well as to the oxide.
Fifteen devices from the same wafer (# 091902-11) were packaged using the
method developed by Shawgo. Stainless steel frames (Microphoto Inc., Roseville, MI)
pressed the device reservoirs against a silicone gasket (125 pm thick, Advanced Bio-
Technologies, Silverdale, WA) and backing plate. A detachable connector board and
gold wire bonding (Gold ball wire bonder, Model 4124, Kulicke and Soffa Industries
Inc., Willow Grove, PA) were used to establish electrical connection between the device
and the external triggering unit, a potentiostat. Wirebonds were mechanically protected
and electrically isolated with two-component epoxy (Masterbond EP42HT, Hackensack,
NJ). Photos of a device packaged in frames and a complete package with a connector
board are shown in Figure 3.1.
(a) (b)
Figure 3.1 Photographs of (a) a packaged device and (b) a packaged device with electrical
connection established by wire bonding through a connector board fixed on frame top using
epoxy. Photos taken by Rebecca Shawgo.
3.2.2 In situ observation setup
The packaged device was fixed inside a plastic petri dish using epoxy (Devcon 5-
minute epoxy). PBS solution (0.15 M P04": 0.15 M CI-, pH 7.2) was filled to completely
cover the device top surface. The dish was placed under an optical light microscope
(Olympus BH-2) with an ultra long working distance 50x objective and 10x eyepiece. A
3-CCD color camera (Hitachi HV-D30) was attached to the microscope to capture real
time video images, which were archived to DV cassettes (Panasonic DV 120) through a
digital video recorder (Panasonic AG-DV2000). The video data were captured and
analyzed using Adobe Premier (Version 6.0) through an IEEE 1394 interface with the
following settings: NTSC DV format, 720 x 480 frame size, 0.9 pixel aspect ratio, and
29.97 frame rate. Figure 3.2 illustrates the in situ experimental setup.
/ Reference electrode
Figure 3.2 Schematic of the in situ observation setup.
3.2.3 Electrochemical test
A Gamry potentiostat (PC 4-300, Gamry Instruments, Warminster, PA) was used
to output the voltammetry profile to the packaged drug delivery devices. The
electrochemical test used a three-electrode system, which included the 50 x 50 ptm anode
gold membranes and a large cathode gold membrane on the device, and a platinum (Pt)
wire serving as the reference electrode.
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One key requirement for the reference electrode is a stable and well characterized
reference potential in the test solution. SCE is a popular reference electrode for common
laboratory use. However, SCE will leak Cl- into the electrochemical cell, which can
change the C1- concentration of the electrolyte and requires the use of a salt bridge to
keep constant C1- concentration in the cell. The bulky size of SCE and salt bridge makes
it unsuitable to be used as an in vivo reference electrode. A platinum wire was chosen
because of its small size and biocompatibility. The commercially available Pt wire has a
very smooth shining surface. Such a Pt electrode however was found to function less
stable in the PBS solution, as shown by the cycle to cycle shift in the gold corrosion peak
potential as well as the difference in the magnitude of peak corrosion rate in the cyclic
voltammograms for a gold foil in PBS solution (see Figure 3.3a).
The reason for the unstable electrochemical behavior was largely due to the high
impedance of the Pt electrode-electrolyte (PBS) interface, which led to a large potential
drop near the interface 3. This made the electric field applied to the working electrodes
highly susceptible to small fluctuations in the interface condition. Roughening the
electrode surface has been found to significantly lower the electrode impedance by
increasing the effective surface area. Various surface roughening procedures have been
developed, such as chemical and electrolytic etching, electrodeposition, oxidation-
reduction cycling, mechanical abrasion, and sputtering4 8. An electrodeposition procedure
developed by Kershner was used in our study to roughen the Pt wire surface 9. The Pt wire
was placed in a solution of 2 % chloroplatinic acid (H 2PtCl6-6H20) and 0.02 % lead
acetate [Pb(CH 3COO) 2-3H 20] as a cathode with respect to a large area platinum foil
anode. A current of 3 mA (120 Current Source, LakeShore Cryotronics, Westerville, OH)
was applied on a Pt wire (0.2 mm diameter, Alfa Aesar, Ward Hill, MA) with 15 mm
long tip immersed in the solution for 2 minute, leading to the deposition of a uniform
coating with thickness approximately 5 gm as measured under an optical microscope.
The deposited Pt coating appeared black due to the high roughness of the electroplated
surface. The term "blackened Pt wire" will be used in this chapter to refer to the reference
Pt wire electrode after the above electrodeposition roughening treatment. The potential of
the blackened Pt wire electrode measured + 0.32 V vs. SCE in PBS (0.15 M C-, 25 °C).
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A more stable electrochemical response was obtained using the blackened Pt wire as the
reference electrode, as shown in Figure 3.3b.
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Figure 3.3 Cyclic voltammograms for a gold foil in PBS using (a) a smooth shiny Pt wire and (b)
a blackened Pt wire as the reference electrode. Two gold foils (10 x 5 x 0.05 mm) were used as
the counter and working electrodes. The current density was calculated by dividing the measured
current by the apparent surface area of the working electrode (1.015 x 10-4 m2).
The following voltammetry profile was applied to each of the 15 devices: One
row of gold anode membranes (Row G in Figure 3.4) was selected as the test row that
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received two sets of cyclic scans. This included 4 cathodic cleaning cycles between -1 to
-1.5 V at 100 mV/sec scan rate, and 4 diagnostic cycles between 0 and 1.5V at 100
mV/sec scan rate. All 15 devices showed a peak corrosion potential at 0.75 (+ 0.03) V
and depassivation potential at 0.04 (+ 0.02) V (Figure 3.5). A square wave voltammetry
(0/0.8 V, 1Hz) was then applied to the other 5 rows of membranes on each device for
different duration of time, ranging from 1 second to 10 minutes. All potential values
were relative to a blackened Pt wire placed approximately 5 mm away from the packaged
device in PBS. All electrochemical tests were performed at room temperature with no
stirring of the electrolyte solution. Each of the packaged devices was examined under the
optical microscope before the electrochemical test. Occasionally one or two membranes
were found broken, which were noted and excluded from later analysis. Besides the test
row of membranes, a maximum of 24 membranes on each device were electrochemically
corroded for the same duration of time using the square wave voltammetry.
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Figure 3.4 Designation of electrodes in the electrochemical and bulge tests. Each anode is
designated by a combination of row (letter) and column (number). Bulge test was performed on
the 12 anodes (marked by circle) after the electrochemical corrosion test.
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Figure 3.5 Typical cyclic voltammograms for gold membranes in the diagnostic scan in PBS
with 0.15 M Cl, pH =7.2, 25 C and 100 mV/sec scan rate.
3.2.4 Bulge test
Following the electrochemical test, the bottom plate of the packaged device was
immediately removed. The remaining corroded device was placed on the bulge test
apparatus described in Chapter 2. Pressure was applied from 0 to 60 psi at 5 psi interval.
At every 5psi interval, the 3D profiles of each membrane were recorded and analyzed.
The device was pressed against a silicon gasket with a 3mm hole so that at most 12
corroded membranes (marked in Figure 3.4) could be bulge tested.
3.3 Results and discussion
3.3.1 Visualization of the gold membrane corrosion process
Figure 3.6 shows a series of real time images of a gold membrane under the
square wave voltammetry with potential alternating between 0 and 0.8 V at Hz
frequency. Non-uniform corrosion was observed to occur first around the membrane
edges, probably due to the non-uniform distribution of potential across the membrane.
The corrosion proceeded from the edges toward the center until the membrane opened.
Another interesting observation is the periodic change of the brightness of the
membrane synchronized with the alternating potential. Comparison of Figure 3.6b and
Figure 3.6c indicated that the membrane seemed to be brighter at the half cycle than at
the integer cycle.
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Figure 3.6 Real time images showing the corrosion process of a gold membrane under a square
wave voltammetry with (a) 0 cycle, (b) 7 cycles, (c) 7.5 cycles, (d) 12 cycles, (e) 17 cycles, (f) 20
cycles, (g) 24 cycles, and (h) 30 cycles in PBS. Scale bar is 50 ytm.
The number of opened membranes on each corroded device was counted and
listed in Table 3.1. The time for the membranes to open varied from less than 1 minute to
several minutes. More than 90% of the membranes on all the 15 devices were opened
after being corroded longer than 1 minute.
Table 3.1 Results of gold membranes opening after corrosion
for different duration of time in PBS.
Corrosion time Total number of Total number of Notes*
(sec) tested membranes opened membranes
1 24 0
3 24 0
5 24 0
7 24 0
10 24 0
15 23 0 F5 broken
17 22 5 E5 & E6 broken
20 23 3 C3 broken
25 24 17
30 24 19
40 22 19 Row D broken
connection
50 24 12 
60 22 20 A1 & C3 broken
240 23 22 F4 broken
600 24 24
*Notes: These membranes were broken when observed under the optical microscope after
packaging and were excluded from the subsequent electrochemical test and analysis. The
membranes were named by the row (letter) and column (number) labels used in Figure 3.4.
3.3.2 Mechanical integrity of corroded membranes
The bulge test on the corroded membranes yielded two types of results, as
illustrated in Figure 3.7 and Figure 3.8. All membranes corroded longer than 7 seconds
burst at a certain pressure, whereas membranes corroded shorter than 5 seconds could be
pressurized up to 60 psi without rupture.
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Figure 3.7 2D profiles of a 15-second
burst under 5 psi pressure.
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Figure 3.8 2D profiles of a 5-second corroded
under 60 psi pressure.
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The bulge test results were summarized in Table 3.2 (for membranes corroded
longer than 7 seconds) and Figure 3.9 (for membranes corroded shorter than 5 seconds).
A trend of decreasing burst pressure with longer corrosion time was clearly seen in Table
3.2. However, membranes corroded for the same duration of time did not necessarily
burst at the same pressure, reflecting the non-uniform nature of the corrosion process. In
Figure 3.9, membranes corroded for longer time also showed a higher center deflection as
well as larger data scatter. It is difficult to extract exact mechanical property data of
these corrode membranes due to unknown membrane thickness and possible variation of
in-plane sizes between membranes. Nevertheless, results in Table 3.2 and Figure 3.9
clearly indicated that the electrochemical corrosion led to a gradual loss of the
mechanical integrity of gold membranes.
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Table 3.2 Percentage of burst gold membranes as a function
of corrosion time and applied pressure.
Burst
ressure
(psi) 0 5 10 15 20 25 30 35 40 45 50 55Corrosion
time (see
7 25 17 50 8
10 17 8 25 17 17 8 8
15 9 64 9 9 9 
17 27 27 9 9 9
20 18 18 64
25 75 25
30 84 8 8
40 100
50 42 50 8
60 100
240 91 9
600 100
--- uncorroded
-o- sec corroded
-o- 3sec corroded
-A- 5sec corroded
. . . .r = . . . ..
0 10 20 30
Pressure (psi)
40 50 60
Figure 3.9 Deflection of gold membranes corroded for different time under the bulge test. Each
data point calculated from N= 4 membranes.
Analysis of the 3D profiles of the corroded membranes revealed another
interesting phenomenon, as shown in Figure 3.10. The uncorroded gold membrane
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showed a flat profile (Figure 3.10a), which was consistent with the slightly tensile
residual stress in the membrane analyzed in Chapter 2. In contrast, a buckled profile was
observed for all membranes corroded longer than 5 seconds, as shown in Figure 3.10b-d.
(c)
Figure 3.10 Typical 3D profiles of gold
5-15 seconds.
(d)
membranes (a) uncorroded, and (b)-(d) corroded for
The roughness and peak-to-valley difference for the corroded membranes were
calculated and plotted in Figure 3.11. A small increase in the membrane surface
roughness was noted with increasing corrosion time. However, the peak-to-valley
difference exhibited a much larger increase over time, which was in agreement with the
observed buckled membrane profiles shown in Figure 3.10.
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Figure 3.11 3D profile data analysis of gold membranes corroded for different duration of time in
PBS. Each data point calculated from N=4 membranes.
3.3.3 Electrochemical disintegration process of gold membranes
Results from the previous section indicated that the electrochemical corrosion led
to a gradual loss of the mechanical integrity of the gold membranes, accompanied by a
rapid transition of the membrane profile form flat to buckled. An examination of the
thermodynamics and kinetics of gold corrosion helped to explain the possible cause for
the buckled profile and to understand the gold membrane disintegration process. Figure
3.12 shows the calculated Pourbaix diagram of gold in chloride solution (0.1 M). Figure
3.13 (Evans diagram) is a duplicate of Figure 3.5 with exchange of the x-y axis and
conversion of the potential relative to SCE for easy comparison with the Pourbaix
diagram. All potentials used in this section are relative to SCE unless otherwise noted.
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* Rq: root-mean-squared roughness
a Rt: peak-to-valley difference
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Figure 3.12 Calculated Pourbaix diagram for gold in water containing 0.1 M chloride ionsl°.
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Figure 3.13 Evans diagram for gold membranes in PBS with 0.15 M C1-, pH =7.2, 25 C and 100
mV/sec scan rate.
Detailed discussions on the gold corrosion can be found in the literature' 1-5. A
brief description about the four regions (shown in Figure 3.13) in the gold
electrochemical behavior is provided below:
The pre-active region (E < 0.9 V) is characterized by close to zero current density
indicating no occurrence of corrosion. The gold surface however is believed to be
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saturated with chloride ions. When the potential exceeds 0.9 V, the formation of a soluble
gold chloride complex leads to active dissolution of gold. Many experimental studies
have confirmed Au3+ to be the main species formed from gold dissolution 14' 16, 17. The
gold surface enters a state of passivity with the formation of a protective oxide film when
the potential is increased above Epass. Epass is defined as the potential where the passive
film growth begins to predominate over dissolution with the current dropping to a very
low level, and generally falls in the range of 1.05-1.2 v13 -15 is. The mechanism for the
passive film formation is explained by oxygen adsorption and/or chloride ion depletion
on the gold surface. The transpassive region (E > 1.4 V) is characterized by breakdown of
the passive film, the evolution of gases such as chlorine and oxygen, and an increase in
the current density. The little peak in the cathodic polarization segment when the
potential is swept back to zero is related to the redeposition of dissolved Au3+ ions. The
anodic dissolution peak is much higher than the cathodic redeposition peak, indicating a
net mass loss of gold after experiencing one voltammetry cycle.
In our study, the gold membranes were corroded by a square wave voltammetry
with potential alternating between 0.32 and 1.12 V vs. SCE (or between 0 and 0.8 V vs.
blackened Pt wire). The upper potential (1.12V) exceeded Epass measured from the
diagnostic scan (1.05 V). Therefore, the gold dissolution was followed by the formation
of a passive film when the potential reached the upper bound in each voltammetry cycle.
This passive film would be broken down when the potential cycled to the lower bound
(0.32V) due to the presence of chloride. Chloride has been known to induce passivity
breakdown in many metals and alloys including gold' 9 -21. The removal of the passive film
exposed the gold surface for corrosion to proceed in the next cycle, as well as the
formation and breakdown of another passive layer.
Figure 3.14 shows a typical current vs. time plot for a row of 5 gold membranes
under the square wave voltammetry. The high current in each half voltammetry cycle
indicated corrosion of gold, while the close to zero current in the other half cycle
indicated the formation and breakdown of the passive film when little gold corrosion
occurred. The peak current varied among different rows of membranes and different
devices. Some membranes showed a decreasing peak current over time. A peak current
range of 2-20 .A was observed for all the devices tested in this study.
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Figure 3.14 A typical current vs. time plot for a row of 5 gold membranes under the square wave
voltammetry in PBS.
The gold membrane corrosion rate can be estimated using Faraday's Law22:
Ita
m =- (Equation 3.1)
nF
where I is the current, t the time, a the atomic weight, n the number of equivalents
exchanged, and F the Faraday's constant (96500 Coulombs/equivalents). For gold, a=197
g/mol, n=3 assuming Au3+ is the main corrosion species. The mass of corroded gold per
cycle of square wave voltammetry was calculated to be in the range of 0.68 to 6.8 ng
corresponding to a peak current of 2 to 20 gA.
Furthermore, assuming uniform corrosion in the thickness direction and a film
density of 19.3 g/cm3, we can estimate the corrosion rate of gold membranes to be 2.8 to
28 nm per second. Therefore, the time needed to completely remove a 250 nm thick gold
membrane would be in the range of 9 to 89 seconds. Although the range agrees with the
observed results, the above calculation is an overestimation by assuming that all the
current passed was used to corrode the exposed gold membranes. In fact, the uniform
corrosion rate assumption contradicts with the observation of non-uniform corrosion
illustrated in Figure 3.6. Moreover, no correlation was found between the peak current
value and the time needed for membranes to open in this electrochemical test. The peak
current did not become zero after all membranes were opened, implying that not 100% of
the passed current was used to corrode the exposed gold membranes. After the
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membranes were fully opened, the electrochemical reaction probably continued to extend
to the gold covered by the oxide passivation layer.
The buckled profiles in Figure 3.10 were most probably a result of plastic
deformation of the corroded gold membranes. It is postulated that the transient formation
of the passive film in each voltammetry cycle led to the accumulation of plastic
deformation, which contributed to the electrochemical disintegration of the gold
membranes. A qualitative analysis is provided below in order to support this hypothesis.
It is well accepted in electrochemistry that the passive film formation involves
oxide growth on top of a noble metal electrode (such as gold or platinum) when an anodic
potential is applied. The mechanism of the anodic oxide film formation at polycrystalline
gold electrodes is believed to proceed by surface chemical processes mainly involving the
following two steps23, as shown schematically in Figure 3.15:
(1) Initial monolayer formation of a two-dimensional compact oxide (a-
oxide) film, which occurs through place-exchange between the adsorbed OH or O species
on the surface and Au atoms within the surface lattice. The Au a-oxide (AuO,
Au(OH) 224 , Au20 32 5, have all been suggested) is anhydrous and only can form up to 3
monolayers26 .
(2) Higher potential and longer time lead to the growth of a multilayer hydrous
oxide (13-oxide) film, probably by continuing injection of ions of the substrate metal and
their migration through the growing film under the influence of the electric filed23. The
Au P-oxide is hydrous and poorly ordered with low density27. Many compositions have
been suggested for the Au -oxide, including AuOH, Au(OH) 3, and a series of
Au 20 3 .nH20 (n ranging from I to 10)26. The Au P-oxide grows with no limiting thickness
with its composition and structure being strongly influenced by factors such as potential,
temperature, pH, and ionic strength. For example, three Au P-oxide states were identified
in the potentiostatic polarization of Au electrodes in 0.5 M aqueous H 2S0 424 , .OM
HC10428 and 0.5 M KOH24 solutions. Another study using ellipsometric and quartz
crystal microbalance techniques found that the -oxide film became increasingly
hydrated as it thickened when grown at constant potential, with a mass to charge ratio and
refractive index consistent with Au20 3-H 2O and later with Au203-2H 20. In contrast, the
13-oxide film formed by multicycling was found to become less hydrated as it thickened
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with time, with a mass to charge ratio and refractive index consistent with Au203 10H20
and later with Au203-2H 20 as the film thickened 2 6.
2H20 -OH...0- +3H+ + d · · e
,a, E I f -x deC * Q + a-oxde
* * * Aulattice S * * *
(a) (b) (C)
Figure 3.15 Schematic of the formation of Au anodic oxides in aqueous solutions. (a) initial
adsorption of OH or O on metal surface, (b) place-exchanged formation of compact Au a-oxide
monolayer, (c) growth of hydrous Au -oxide film under higher potential and/or with longer time.
Redrawn after Burke27.
The growth kinetics of Au anodic films was experimentally determined by a
number of researchers to follow the logarithmic growth law2 4' 28, 29. However, some
researchers found an inverse logarithmic relation2 4 (l/q oc -logt, here q is the oxide
charge reduction density, a quantity proportional to the oxide thickness, and t is the
growth time), whereas other researchers claimed a direct logarithmic relation2 8
(q oc logt). The extracted slopes of the logarithmic curves vary greatly in different
studies, the interpretation of which remains controversial. Two and even more
distinguishable kinetic regions have also been reported in many studies24' 28, presumably
corresponding to the growth of Au a-oxide and various P-oxides.
It is well known that the thermal oxidation of Si and metals could induce stress,
which includes the thermal stress and internal stress generated during the film growth.
The thermal stress is not a factor in the formation of the gold passive film in our study.
However, the growth of the gold oxide film could induce stress in both the oxide film and
the gold membrane (substrate). In fact, stress generation has been reported in the anodic
oxidation of a number of metals such as aluminum3 0 (Al), tungsten 3' (W), titanium3 2' 33
(Ti), zirconium34 (Zr), and nickel3 5 (Ni).
Stresses in the anodic oxide films include the volume-generated stress and
electrostrictive stress 32' 36. The electrostrictive stress is usually insignificant because of
the weak electric field used in the anodic polarization. Kim's study confirmed that the
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electrostrictive stress constituted less than 10% of the total stress during the growth of
anodic oxide films on a W electrode3 6. The volume-generated stress is closely related to
the Pilling-Bedworth ratio37 (PBR), defined as the volume of the metal oxide to the
consumed metal volume:
PBR= V metal oxide produced M d
VieBRco ue- -- (Equation 3.2)
Vmetal corumed amD
where M and D are the molecular weight and density of the metal oxide with composition
(Metal)a(Oxygen)b; m and d are the atomic weight and density of the metal. The sign and
magnitude of the volume-generated stress are related to (1-PBR). A positive sign
indicates tensile stress and a negative sign indicates compressive stress in the oxide film.
A larger absolute value of (-PBR) implies a higher stress38.
PBR values for most metals fall in the range of 0.53 3 9 . No PBR data is available
for gold, probably because of the unstable nature of gold oxides. Data of the physical
properties of gold oxides are also scarce. Nevertheless, we can estimate the PBR for the
Au-Au2 03 system, using available density data of bulk Au20 3 (10.58 g/cm3 )40 and Au
(19.3 g/cm3 ), molecular weight of Au20 3 (442 g/mol), and atomic weight of Au (197
g/mol). The calculated PBR (=2) is higher than many metals, suggesting that high stress
could occur in the gold oxide film. A few GPa stress was measured during the formation
of the first monolayer oxide for Ni3 5, which has a PBR of 1.6539. It is therefore
reasonable to assume that GPa level stress could be generated during the formation of the
Au a-oxide film in our study.
The stress in the underlying gold membrane (Au) is then directly related to the
oxide film stress (Au203) by applying the force equilibrium condition:
a = Au203 (z)dz (Equation 3.3)
where tA and tAu2o3 are the thicknesses of the gold membrane and oxide respectively.
Although the stress distribution in the gold membrane is unknown, it is reasonable
to assume that the gold area adjacent to the Au/oxide interface has the highest stress
considering that this is the region that is perturbed most by the oxide growth. It is thus
plausible that high stress in this area could even exceed the yield strength of gold (around
300 MPa according to the estimation in Chapter 2) and induce plastic deformation of the
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substrate membrane. As a supporting example of the above argument, plastic deformation
of 100 gpm thick Si substrates (which is much thicker than the submicron thick gold
membrane in our study) has been found to occur during the oxidation process4 1.
It is also possible that the failure (or opening) of the corroded gold membrane
occurred when there was still some gold mass remaining. With the accumulation of
plastic deformation after each voltammetry cycle, a critical state could be reached when
the exerted stress in a new voltammetry cycle exceeded the fracture strength of the
deformed gold membrane, causing it to fail. Therefore, the electrochemical disintegration
of gold membranes under the square wave voltammetry is a result of the combined effect
of membrane thinning due to active dissolution and accumulation of plastic deformation
due to the transient formation of a passive film.
The in situ observation setup is a useful tool to visualize the gold membrane
disintegration process. Further investigation using other in situ techniques may provide
more quantitative experimental data of the composition, structure and stress state of the
oxide layer, which in turn provides useful guidance to effectively improve the operation
reproducibility of this drug delivery device.
3.4 Conclusions
Combination of the in situ observation and bulge test provided valuable
information about the gold membrane disintegration process. Real time images recorded
from a CCD camera showed non-uniform corrosion occurring first around the membrane
edges. More than 90% of the membranes on the 15 devices tested in PBS were opened
after being corroded longer than 1 minute. The decrease in the membrane burst pressure
with longer corrosion time under the bulge test confirmed a gradual loss of mechanical
integrity of the gold membranes due to corrosion. The morphology observation revealed
a buckled profile of the corroded membranes, which was probably correlated with the
plastic deformation induced by the transient formation of a passive film on top of the
gold membrane. The gold membrane electrochemical disintegration occurred by a
combination of membrane thinning through active dissolution and accumulation of
plastic deformation.
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4 In vitro release of BCNU
4.1 Introduction and motivation
1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU), also called carmustine, is a member
of the most extensively used antitumor agents1' 2. It was chosen as a model therapeutic
compound to demonstrate the localized controlled release capability of the MEMS device
in vivo. Because of the complex metabolic process and high cost associated with the in
vivo studies, in vitro evaluation of BCNU release serves as useful controls to explain the
in vivo study results. It also provides a quick and cheap method to investigate some of the
problems encountered in the in vivo studies. This chapter first discusses control of 4C-
BCNU leakage from packaged devices, which is an important prerequisite for the release
study and yet has been found to be a nontrivial task. A series of BCNU in vitro release
experiments are presented, followed by discussion on the effects of drug formulation and
packaging method on the BCNU in vitro release kinetics.
4.2 Experimental methods
4.2.1 Device fabrication
Devices were fabricated using the same process described in Chapter 2. The gold
electrodes on some devices (from Wafer # 070103-3) were patterned by lift-off of the
evaporated gold film. The electrodes on the other devices (from Wafer # 070103-6) were
patterned by wet etching of the sputtered gold film.
4.2.2 Device packaging
Devices were packaged using two methods with different frame materials and
packaging sequence:
(1) Stainless steel frame package
This is the same method described in Chapter 3. A neoprene gasket (1/16" thick,
McMaster-Carr Supply Co, Los Angeles, CA) was used instead of the silicone gasket
because the silicone gasket was found to be permeable to BCNU in the in vivo release
study. Accordingly, a thicker stainless steel middle frame was used to accommodate the
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gasket thickness difference. A masking tape (9144, Ideal Tape Co., Lowell, MA) was
also used, either alone or in combination with the neoprene gasket, to seal the filled
reservoirs and test for leakage. After wire bonds were made and mechanically
strengthened by epoxy (Masterbond EP42HT, Hackensack, NJ), the frames were opened
for chemical filling. The devices were resealed in their frames after filling using bolts and
nuts (# 000-120, Small Parts Inc., Miami Lakes, FL).
(2) Pyrex package
This method was developed to increase the capacity of the device and overcome
the problem of incomplete payload release from the stainless steel frame package. Two
Pyrex chips (500 gm thick) containing machined "macro-reservoirs" were bonded to the
backside of the drug delivery device. A solid Pyrex plate was then bonded to the back of
the macro-reservoir plate to enclose the macro-reservoirs. Chemical filling was
performed along the channels machined on one of the two Pyrex chips (see Figure 4.1).
The four edges of the front side of the device was connected to a stainless steel frame by
epoxy for easy handling of the package and for attachment of a connector board to
establish electrical connection between the device and the potentiostat.
_,Solid Pyrex Back
Plate
Machined
Channels for
Filling
> Pyrex Macro-
reservoir Plate
- Silicon MEMS
Device
(a) (b)
Figure 4.1 (a) Schematic showing the Pyrex package design. (b) Photograph of an assembled
device. Schematic drawn by Malinda Tupper. Photo taken by Lenny Rigione.
Two methods were used to bond the Pyrex chips. One method is to use UV epoxy
(1-20542 cationic epoxy, Dymax Corporation, Torrington, CT). A silicone thick film
with patterned grid lines was first fabricated from a silicone mold and glued onto a glass
slide. A small amount of epoxy was spread along the film using a squeegee. The Pyrex
chip was then coated with a thin uniform layer of epoxy by being pressed against the
silicone film and lift up. The epoxy coated chip was placed on top of the Si device or
another Pyrex chip and exposed under UV light (Cure Spot 50, Dymax Corporation,
Torrington, CT) for 20 seconds. The bonded part was left at room temperature for 4-5
hours for the epoxy to completely cure. Another method is to use the silicon-Pyrex
anodic bonding and Pyrex-Pyrex diffusion bonding, which is expected to achieve real
hermetic sealing. Details about the Pyrex chip machining, anodic and diffusion bonding
can be found in Ho Duc's thesis3. All devices for the in vitro release studies presented in
this chapter were bonded using UV epoxy.
4.2.3 Chemical filling
Microinjection was used to fill the reservoirs using a micropump system, which
consists of a UMP-1 Ultra Micro Pump with Micro-1 controller and a Kite-R
micromanipulator with a TB-1 tilting base (all from World Precision Instruments,
Sarasota, FL). Solutions were injected from a 10 gtL syringe with 32 Gauge needles
(Hamilton Company, Reno, NV). The microinjection was performed under a
stereomicroscope (PZMT, World Precision Instruments, Sarasota, FL).
Chemicals used for the filling included BCNU (Bristol-Myers Squibb Co.,
Evansville, IN), radiolabeled BCNU (' 4C-BCNU, Moravek Biochemicals, Brea, CA), and
poly ethylene glycol (PEG, Mw 200 or 400, CarbowaxTM , The Dow Chemical Company,
Midland, MI). For the stainless steel frame packaged devices, the sequence of chemical
injection was 20 nL PEG (dissolved in ethanol, 10 vol%), 15 nL 14 C-BCNU (dissolved in
ethanol) for 3-5 times, and 25 nL PEG (dissolved in ethanol, 80 vol%). For the Pyrex
packaged devices, a mixture solution containing 14C-BCNU, unlabeled BCNU, and PEG
was used. The mixture solution was made by first dissolving 14C-BCNU (approximately
50 gCi) and BCNU (approximately 160 mg) in ethanol (0.1-0.2 mL) in a 1 mL glass vial,
mixed on a vortex machine (Vortex-Genie 2, VWR Scientific Products), and dried under
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flowing nitrogen to evaporate the ethanol. The weight change of the drug containing vial
was monitored on a balance (AE 100, Mettler-Toledo, Inc., Columbus, OH) to ensure
complete removal of ethanol. A 10 jpL syringe with 26 Gauge needles (Hamilton
Company, Reno, NV) was used to dispense PEG and BCNU by the specified volume
ratio in a 1 mL glass vial with tapered interior. The BCNU density was measured to be
1.2 g/mL by a microbalance. BCNU (light yellow) and PEG (clear) did not mix readily,
and approximately 1-minute vortex led to a uniform mixture of the two agents with no
observable color separation in the solution. The mixture solution was injected along the
channel into the reservoirs. Ethanol instead of water was used as the dissolving medium
because BCNU has a relatively longer half-life in ethanol (74 days4) than in aqueous
media (10 to 20 minutes 5' 6). PEG was initially chosen to help reduce the drying stress on
the membrane. It was later found out that a more important role of PEG was to adjust the
BCNU release kinetics, as discussed in Section 4.3.3.
The actual 14 C-BCNU activity ordered from Moravek usually deviates from the
specified value and tends to change from one order to another. Therefore, the actual
activity was checked for each order by scintillation counting of a known volume of 14C-
BCNU/ethanol solution. Each time packaged devices were filled, 2 or 3 bare devices
were also filled with the same amount of radioactive solution to serve as dosage controls.
The test sample for the ' 4C detection was placed in a 7 mL scintillation vial,
mixed with 5 mL ScintiSafe fluid (Fisher Scientific, Atlanta, GA), and counted on a
Packard Tri-Carb liquid scintillation analyzer (Model 2200CA, Perkin-Elmer Life
Sciences, Downers Grove, IL). Raw DPM (disintegrations per minute) data were
converted to activity in microcuries (Ci) by a conversion factor of 2.2 x 106 DPM/gCi.
4.2.4 Leak test
In vitro leak testing was performed to evaluate the hermeticity of the packaged
devices filled with 14C-BCNU. Devices were filled and packaged without attachment of
the connector boards. The four outer edges of the stainless steel package were covered by
the 2-component epoxy (Masterbond EP42HT, Hackensack, NJ), and the edges of the
Pyrex package covered by UV epoxy. Packaged devices were immersed in a 20 mL glass
vial with 16 mL DI water (or PBS solution) placed on a stirrer with mild stirring (stirrer
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setting at -3) to ensure thorough mixing. One mL samples were taken at pre-determined
time points (3-4 times on the first day and once every day on following days), and the
testing medium replenished with 1 mL DI water (or PBS) after removal of each aliquot.
The sample 14C content was analyzed by scintillation counting as described in the
previous paragraph. The leakage percent was calculated for each packaged device, with
the total 14C loading determined from scintillation counting of control devices that were
filled with the same volume of solution and at the same time when devices for the leak
testing were filled. The leak test was performed at either room temperature or 37 C by
keeping the glass vial in a water bath.
4.2.5 In vitro release studies
Each packaged device filled with 14C-BCNU was placed in a 20 mL glass vial
containing 16 mL PBS (0.15 M C-, pH=7.2) mildly stirred (stirrer setting at -3). Devices
were activated using the same voltammetry profile described in Chapter 3, with 4 cycles
of cathodic cleaning from -1.0 to -1.5 V, 4 cycles of diagnostic scan from 0 to 1.5 V, and
10-minute square wave voltammetry between 0 and 0.8 V. All potentials were relative to
a blackened Pt wire placed about 5 mm away from the device in the same PBS containing
glass vial. One mL samples were taken more frequently immediately after activation
(every 20 or 30 minutes) than at later times (2 or 3 times a day). One mL PBS was added
to the release medium after removal of each aliquot. The sample 4C content was
analyzed by scintillation counting as described in Section 4.2.3. The percentage of
payload release was calculated, with the total 14C loading determined from scintillation
counting of control devices that were filled with the same volume of solution and at the
same time when devices for the release studies were filled.
4.3 Results and discussion
4.3.1 Origin of 14C-BCNU leakage
Leakage of 14C-BCNU was found in the first in vivo release study and the cause
was attributed to the silicone gasket being permeable to BCNU7 . Soaking a device
packaged using the silicone gasket in water led to 50% leakage of the radioactivity within
24 hours. Different sealing materials were tested to find a better gasket material. The
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neoprene gasket seemed to have better sealing property than the 9144 tape. However,
there was still an appreciable amount of leakage within 2 days, as shown in Figure 4.2.
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Figure 4.2 Leak test of stainless steel frame packaged devices with different gasket sealing
materials. Device 1 was sealed using neoprene gasket and 9144 tape, Device 2 sealed using only
9144 tape, and Device 3 sealed using only neoprene gasket. Each device was filled with 0.31 pCi
'
4C-BCNU. Test performed at 37 °C in PBS.
Leakage of 14 C-BCNU was still observed for packaged devices with all inner and
outer edges of steel frames covered by epoxy, and was stopped only when all the gold
membranes were also covered by epoxy, as shown in Figure 4.3.
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Figure 4.3 Leak test of stainless steel frame packaged devices sealed using neoprene gasket.
Device 1 had all inner and outer edges of steel frames covered by epoxy, and Device 2 had all
inner and outer edges of steel frames, and all gold membranes covered by epoxy. Each device
filled with 0.31 gCi 14C-BCNU. Test performed at 37 °C in PBS.
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Further optical microscopy observation of the gold membranes revealed two types
of morphologies after the reservoirs were filled with 14C-BCNU. Most of the membranes
remained smooth and shiny as they were before the filling (Figure 4.4). A few other
membranes however, showed some stained pattern after the filling (Figure 4.5).
(a) (b)
Figure 4.4 Optical micrographs of a gold membrane (a) before and (b) after 14C-BCNU/ethanol
solution was filled, showing no change in the membrane morphology.
(a) (b)
Figure 4.5 Optical micrographs of a gold membrane (a) before and (b) after 14C-BCNU/ethanol
solution was filled, showing stained morphology after the filling.
When the stained membranes were covered by epoxy, a dramatic decrease in the
leakage rate was observed (see Figure 4.6). All these results indicated that the defects on
the gold membranes were an important source of leakage for the small molecule 14C-
BCNU (Mw=181). These defects allow the penetration of the ethanol solution
(containing '4C-BCNU) through the gold membranes to the surface and leave stains after
the ethanol evaporates.
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Figure 4.6 Leak test of three stainless steel frame packaged devices patterned by lift off, sealed
using neoprene gasket, with all inner and outer edges of steel frames, and all stained gold
membranes covered by epoxy. Device 1 and Device 2 each filled with 0.0315 jCi 4C-BCNU
loading, and Device 3 filled with 0.015 pCi 14C-BCNU loading. Test performed at room
temperature in deionized water.
All the leak tests described above were performed on devices with evaporated
gold membranes. On average, 5 evaporated gold membranes were stained if all the 34
reservoirs were filled with the '4C-BCNU/ethanol solution for one device. In contrast, at
most 2 sputtered gold membranes were observed to be stained if all the 34 reservoirs
were filled with the same volume of '4C-BCNU/ethanol solution for one device. Leak test
on a packaged device with sputtered gold membranes also showed a lower leakage rate
(-7% over one month, see Figure 4.7) than devices with evaporated gold membranes
(-10% over 10 days, see Figure 4.6). All this indicates that wafers with sputtered gold
films (electrode patterning by wet etching) indeed have a higher device yield and better
membrane quality than wafers with evaporated gold films (electrode patterning by lift
off).
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Figure 4.7 Leak test of one stainless steel frame packaged device with sputtered gold membranes
patterned by wet etching, sealed using neoprene gasket, with all inner and outer edges of steel
frames. Device filled with 0.012 pCi '4C-BCNU. Test performed at room temperature in
deionized water.
Figure 4.8 shows the leak test result on two stainless steel frame packaged device
with sputtered gold membranes. The much higher percentage of '4C-BCNU leakage
arises from two differences: One difference is that the inner edges of the steel frames on
this device were not covered by epoxy. The other difference is a much larger mass
contained in each filled reservoir of these two devices. For all the other devices tested
before Figure 4.8, each filled reservoir contained 2 nL PEG and about 2 nCi '4 C-BCNU.
The mass for 2 nCi 4C-BCNU is 6.8 ng calculated according to the specific activity of
'
4C-BCNU (53 mCi/mmol). For the devices tested in Figure 4.8, besides the 2 nL PEG
and 6.8 ng 14C-BCNU, another 20 nL PEG was filled so each reservoir was almost full.
The much higher leakage rate for the devices in Figure 4.8 clearly showed that the
stainless steel package was leaky, most probably because the neoprene gasket did not
form a hermetic seal against the filled reservoirs. Although covering the inner edges of
the steel frames can solve the package leak problem, it is not an ideal solution. When
sequential release of payload from different rows of filled reservoirs is desired, opening
one row can lead to outflow of the payload from adjacent rows of reservoirs through the
opened membranes.
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Figure 4.8 Leak test of two stainless steel frame packaged devices sealed using neoprene gasket,
with all outer edges of steel frames. The 4 C-BCNU for both devices was 0.022 pCi. Each filled
reservoir also contained 22 nL PEG. Test performed at room temperature in deionized water.
Figure 4.9 shows the leak test of a Pyrex packaged device. The leakage rate of
'
4C-BCNU before Day 12 was essentially zero, indicating good hermeticity of the
package. The abrupt increase in the leakage percentage after Day 12 suggests that the UV
epoxy was not durable to resist the attack of BCNU for long time. It is hoped that the
anodic and diffusion bonding method will lead to real long term hermetic seal of the
package.
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Figure 4.9 Leak test of one Pyrex packaged device filled with
PEG with 80:20 volume ratio and a total radioactivity of 0.25
room temperature in deionized water.
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4.3.2 In vitro BCNU release kinetics
4.3.2.1 Stainless steel frame packaged devices
Two in vitro release tests were performed on the stainless steel frame packaged
devices. The first test studied the release kinetics of 14C-BCNU from devices filled with
predominantly PEG in volume (22 nL) relative to 4 C-BCNU (less than 2 nL), as shown
in Figure 4.10. Each activation was followed by a rapid increase in the 4C counting and
establishment of equilibrium within 30 minutes after activation. Approximately 40 % of
the initial 4C loading was detected from the release medium, although all the membranes
were opened as confirmed by the optical microscopy examination. The remaining 60 %
was recovered by subsequently soaking the unpackaged devices in saline and analyzed by
scintillation counting. The neoprene gasket was found to contain most of the
radioactivity, with 45 % of the radioactivity recovered after soaking for three days. The
inner edges of the steel frames of the two packaged devices were not covered by epoxy.
Although there was concern about the cross-talking between neighboring rows due to
incomplete seal, the radioactivity measurement did not show obvious difference in the
amount of 14C released from each row, probably because the time interval between each
activation was too short for the cross-talking to show an effect.
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Figure 4.10 Cumulative percentages of 14C-BCNU released from two devices packaged using
stainless steel frames and neoprene gasket. Each activation (denoted by the dashed line)
corresponds to opening of one row of reservoirs with 0.01 pCi loading. Each filled reservoir also
contained 22 nL PEG. Test performed at room temperature in PBS.
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The second test evaluated the 14 C-BCNU release kinetics from devices filled with
different volume ratio BCNU/PEG (see Figure 4.11). The silicone gasket was used
instead of the neoprene gasket to seal the reservoirs. Although the silicone was known to
be permeable to BCNU, it was expected that the much thinner silicone gasket (125 Pim
thick) would not trap as much radioactivity as the neoprene gasket (1.58 mm thick). The
results show an interesting trend of higher percentage of 14C-BCNU released with higher
percentage of PEG in the initial formulation. The time to reach plateau 14C level was also
faster with more PEG added into the reservoir.
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Figure 4.11 Cumulative percentages of 14C-BCNU released from four devices packaged using
stainless steel frames and silicone gasket. Each activation (denoted by the dashed line)
corresponds to opening of 10 reservoirs with half of the initial loading. Each filled reservoir
contained 20 nL mixed solution of 14C-BCNU/BCNU/PEG with different BCNU/PEG volume
ratio. Test performed at room temperature in PBS.
4.3.2.2 Pyrex packaged devices
The Pyrex package allows the in vitro release test to be performed with longer
time interval between activations. The Cumulative release results of 14C-BCNU from 4
Pyrex packaged devices are shown in Figure 4.12. Incomplete release of payload and
sluggish kinetics were observed for the devices filled with 100 % BCNU. In contrast, the
other three devices showed close to 100 % release of the radioactivity. The time to reach
equilibrium 14C level was fastest for the device filled with 80 % PEG (approximately 6
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hours), and slightly longer for the other two devices filled with 50 % and 20 % PEG (15
- 20 hours).
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Figure 4.12 Cumulative percentages of 14C-BCNU released from four devices packaged using
Pyrex plates. Each activation (denoted by the dashed line) corresponds to opening of 10
microreservoirs with half of the initial loading. Each device was filled with a mixed solution of
'
4C-BCNU/BCNU/PEG with different BCNU/PEG volume ratio. The BCNU loading was 1.2 mg
in each of the three devices (100 % BCNU, 80 % BCNU and 50 % BCNU) and 0.96 mg in the
device with 20 % BCNU. Test performed at room temperature in PBS.
4.3.2.3 Effects of drug formulation and packaging method
In vitro release results from the previous two sections clearly show that co-
formulation of Polyethylene glycol (PEG) greatly enhanced the BCNU release kinetics,
in terms of both the percentage of payload release and the time to reach equilibrium 4C
level. The sluggish release kinetics from devices filled with 100 % BCNU can be
explained by the high lipophilicity (or hydrophobicity) of BCNU. PEG is a non-toxic
water soluble polymer. Conjugating biomolecules with PEG, a process known as
PEGylation, is an established method for improving the pharmacokinetics and
pharmacodynamics of many protein and liposomal drugs 8. Although the BCNU in our
study was not PEGylated, the presence of PEG helped to drive the out diffusion of BCNU
when the membranes were opened, leading to more complete and rapid release of
payload.
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The Pyrex package also showed obvious advantages over the stainless steel
framed package. The capacity of the Pyrex packaged devices was greatly increased
comparing to the stainless steel frame packaged devices because of the addition of the
two macroreservoirs with an approximate volume of 9 ,gL, which is much larger than the
total volume of the 34 microreservoirs (0.85 !IL). Addition of the Pyrex plates increased
the thickness of the package. But this increase was offset by the decrease in the lateral
dimension of the package due to elimination of the steel frames. The overall volume of
the Pyrex package is in fact smaller than the steel frame package. One limitation is that
only two release events can be achieved with the current Pyrex package, yet it is possible
to modify the design and increase the number of macroreservoirs on one Pyrex chip in
order to achieve more independent release events.
Another advantage of the Pyrex package is the more complete release of payload.
With the same BCNU/PEG formulation, the time to reach plateau 4C-BCNU level after
activation for the Pyrex packaged devices (several hours) was longer than for the
stainless steel frame packaged devices. One possible reason is that the drug mixture was
directly injected into each microreservoir for the stainless steel frame packaged devices.
Whereas it was impossible to directly address individual microreservoir when filling
along the channels on the Pyrex chip and completely fill the micro and macroreservoirs
(as the BCNU/PEG solution tended to creep along the channel and wet the end of the
channel when the reservoirs are close to full, which prevented sealing). After the
membranes were opened, the remaining air bubbles inside the reservoirs could hinder the
out diffusion of BCNU, delaying the time to reach equilibrium.
4.4 Conclusions
The in vitro leak test results presented in this chapter illustrate the importance of
fabricating high quality gold membranes through processing optimization. Co-
formulation of polyethylene glycol (PEG) with BCNU effectively enhanced the release
kinetics of BCNU in vitro. The Pyrex package demonstrated obvious advantages over the
stainless steel frame package with greatly increased capacity and more complete payload
release. Results from these experiments serve as controls as well as useful guidance for
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the in vivo BCNU release kinetics study and tumor effect study presented in the next two
chapters.
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5 Release kinetics of 14C-BCNU in vivo
5.1 Introduction and motivation
Understanding the release kinetics of BCNU from the MEMS device is important
as it may differ from the known pharmacokinetics of BCNU administered by injection or
other methods. For the in vitro release of ' 4C-BCNU presented in the previous chapter, all
the released radioactivity can be collected from the release medium for direct analysis of
the release kinetics. The drug released from the devices in vivo, however, experiences
metabolism, partition among different organs, and excretion. This necessitates a good
understanding of the in vivo pharmacokinetics of 14C-BCNU in order to choose an
appropriate model to study its release kinetics from the drug delivery device in vivo.
Available pharmacokinetic data using 14C-BCNU indicate that the compound and
its metabolites are accumulated in the liver, kidney and lungs, and that approximately
78% of a radioactive dose injected intraperitoneally, subcutaneouly, or taken orally, is
excreted from mice within 24 hours. The plasma 14C concentration, though only a small
portion (1-5%) of the dose, remains constant in the plasma for relatively long duration
with a 67-hour half life'. It is therefore appropriate to measure pulses of BCNU release
from the drug delivery device using plasma samples to obtain the temporal release
kinetics. This approach however is limited by the relatively low sensitivity of the
conventional liquid scintillation counting (LSC) with respect to the low plasma 4C level.
An alternative tool of isotope detection is the accelerator mass spectrometry (AMS), a
highly sensitive method for quantifying extremely low concentrations of radioisotopes
with ultrahigh precision2' 3. This chapter introduces a collaborative study to utilize the
AMS facility at Lawrence Livermore National Laboratory (LLNL) for evaluating the
release kinetics of '4C-BCNU in vivo4 .
5.2 Experimental methods
5.2.1 Device fabrication and packaging
Devices (from Wafer # 070103-3) were fabricated using the same process
described in Chapter 2. The gold electrodes were patterned by lift-off of the evaporated
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gold film. Devices were packaged into stainless steel frames with neoprene gaskets
(McMaster-Carr Supply Co, Los Angeles, California) to seal the reservoirs. Wirebonds
connected the bondpads on the device to connector boards and Teflon coated cables
(UT3201TFK16, Axon' Cable Inc., Schaumburg, IL). Wirebonds were mechanically
protected and electrically isolated with epoxy (Masterbond EP42HT, Hackensack, NJ). A
blackened platinum wire (approximately 6mm long) was soldered to exposed end of one
cable with epoxy covering the soldering joint to be used as an in vivo reference electrode.
Four devices were filled with ethanol solutions of PEG (Mw 200) and 14C-BCNU
(Moravek Biochemicals Inc., Brea, CA) using a UMP-1 Ultra Micro Pump with Micro-i
controller and a Kite-R micromanipulator with a TB-I tilting base (all from World
Precision Instruments, Sarasota, FL) under the stereomicroscope. Each device had three
rows of reservoirs filled, with each row containing 0.01 !xCi 14C-BCNU. Each filled
reservoir also contained 22 nL PEG.
5.2.2 Animal protocol
The in vivo release study was performed in Dr. Henry Brem's group at Johns
Hopkins Medical Institutions (JHMI). The animal study protocol was approved by the
Animal Care and Use Committee of JHMI before implementation of any procedure.
Female rats (Fisher 344, weight 150-200 g) were purchased from Charles River.
Animals were given standard rat chow and water ad libitum at the JHMI Animal
Facilities.
Devices were sterilized by gamma irradiation using a Markl-68 irradiator (JLS
Shepherd, Glendale, CA) with a Cerium 137 source for a total dose of 40 Gray. Prior to
surgery, the rats were anesthetized with an intraperitoneal injection of 0.6 mL of a stock
solution of ketamine hydrocholoride 25 mg/ml, xylazine 2.5 mg/ml, and 14.25 % ethyl
alcohol diluted in 0.9 % NaCl solution. The skin of the left flank was shaved and prepped
with betadine. Under sterile conditions, an incision (approximately 1 cm) was made in
the skin of the flank to form a subcutaneous pocket caudally. Devices were implanted
subcutaneously with the electrodes facing the anterior flank and the cable exiting through
the incision. The incision was closed with autoclips. Post-operative analgesics were given
following every surgical procedure using a subcutaneous injection of buprenorphine
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(0.1 mg/kg). All operating procedures were performed using sterile technique, with all
instruments autoclaved and sterile gloves and masks worn throughout the procedure.
Activations were performed on three devices at 3-hour intervals. The applied
voltammetry included four cathodic cleaning cycles from -1.0 to -1.5 V, four diagnostic
scan cycles from 0 to 1.8 V, and 10-minute square wave voltammetry between 0.2 and
1.4 V, all relative to the blackened Pt wire reference electrode.
The femoral artery catheterization was performed on each rat one hour before the
device activation. A small incision was made into the femoral artery to allow insertion of
a catheter that was used to remove blood samples and inject sterile saline. Blood samples
of 100 ptL were taken every 20 to 30 minutes before and after each activation. Sterile
saline with 10 vol% heparin was injected through the catheters after taking each blood
sample to replace the blood volume lost as well as to keep the catheters from clogging.
The rats need to be kept at the anesthetized state by injection of 0.2 mL anesthetic
solution every two hours because their movement could displace the catheter and affect
the blood sample taking process. This catheterization procedure was problematic until the
technique could be perfected as two rats expired before completing all the scheduled
activations. Blood samples were centrifuged at 6000 rpm for 5 minutes to yield
approximately 75 pL plasma for each sample. The plasma 14C concentration was
measured by AMS, as described in the section below.
Controls included animals with an unactivated device and with subcutaneously
injected '4C-BCNU. The study was designed to have one rat receive three subcutaneous
injections of 0.15 mL sterile saline solution containing 0.01 CCi 14C-BCNU at 3-hour
intervals. It was later found out that the 14C-BCNU stock received from Moravek had a
higher activity than the specified value. The actual 14C loading for each injection was
0.014 jtCi as determined by LSC. Two devices activated in vitro in saline were used as
in vitro controls.
Animals were euthanized by either CO2 inhalation or a sodium pentobarbital
overdose (200 mg/kg, to effect) at the conclusion of experiments. Devices were explanted
and shipped to MIT for optical microscopy inspection (Olympus BH-2).
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5.2.3 AMS analysis of plasma 14C concentration
Detection of 14C (half life 5760 years) can be made either by measuring the decay
(such as liquid scintillation counting, or LSC) or by directly counting the radiocarbon
atoms using the Accelerator Mass Spectrometry (AMS). Use of LSC on small samples
with low 14C activity is often limited by high backgrounds, low specificity and low
counting efficiency. On the other hand, AMS can detect one 14C ion in a quadrillion
(1015) other ions (equivalent to 0.14 DPM) with a precision of 0.5-1%5 . The high
detection sensitivity (105 to 106 higher than LSC) arises from the design of the
spectrometer, which allows the molecular dissociation process at the accelerator and
charge detection at the end (see Figure 5.1). A number of studies have also validated the
AMS against LSC for analyzing 14C labeled drugs in human and animal body fluids with
superior analytical sensitivity and accuracy6 -8.
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Figure 5.1 Schematic of the accelerator mass spectrometer for 14C detection. Courtesy of Paul
Henderson.
The high sensitivity of AMS requires strict contamination control in the sample
preparation and handling to maintain sample integrity9 . This was especially important in
our study where high 14C level work (for LSC of the urine samples) had been performed.
Nine swipes were taken of all the work area related to the in vivo test, including cages,
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the centrifuge equipment, doorknobs, sink handles, the microscope stage and workbench.
These swipes and three blank blood samples were analyzed by AMS. The results showed
acceptable contamination control level except the centrifuge equipment. In the
subsequent release kinetics study, great care was taken to avoid contact of the pipette
with the outside of the centrifuged Eppendorf tube when transferring the plasma samples.
A pilot study was also conducted on AMS analysis of 5 plasma samples from a rat
with one subcutaneous injection of 0.6 nCi 14C-BCNU (dissolved in 0.1 mL ethanol) and
6 plasma samples from a rat with one activated device filled with approximately 0.6 nCi
14C-BCNU loading. The purpose of the pilot study was to establish experimental
protocols of using AMS for the release kinetics study.
The AMS analysis was made at the Center for Accelerator Mass Spectrometry at
LLNL. Plasma samples shipped from JHMI were thawed at room temperature, vortexed
and centrifuged in order to obtain a homogeneous liquid sample. A 25 gL aliquot of each
sample was placed in a quartz tube and dried by vacuum centrifuge. The sample was
converted to CO2 by combustion, and was quantitatively reduced to graphite in the
presence of zinc and titanium hydride condensing onto catalytic iron at -500 °C for 4
hours l°. The graphite samples were introduced into the spectrometer for three to seven
replicate measurements to a precision of 3 % or better.
AMS measures an isotope ratio, expressed as 14C per mass of carbon5:
14C q -14C 4IT 4 _Ctrace ± 4 Cnatural 1 ctrace ' 4 Cnaturai Ctrace = g Rnatural
14C measure trace Cnatu r a Cnatural n tural
(Equation 5.1)
where 14Ctrace and Ctrace are the radioactivity and mass of sample, and 14 CnaturaI and Cnatura
the radioactivity and mass of the control sample of a similar tissue. Ctrace can be neglected
because usually a picomole (10-12) or less radiolabeled compound is contained in
milligram-sized samples. Rnatra, in our study used the AMS measurement of the baseline
plasma sample for each rat that was taken prior to the device implantation or injection.
The unit of the AMS measurement is called "Modem". 1 Modem is equivalent to 6.11
fCi 4C/mg carbon, or 97.89 amol '4C/mg carbon5 . The plasma 14C concentration (unit:
fCi/pL), therefore, can be calculated by:
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Plasma 14C conc.= (Rmeasure - Rnaral )x 6.11 ai x C% x Plasma density
mg C
(Equation 5.2)
Plasma normally contains 3% carbon by weight. The plasma samples in our study,
however, also contained a small amount of heparin (a carbon containing compound).
Total percent carbon in the blood plasma was measured with an Exeter CE-440 elemental
analyzer (Exeter Analytical, Inc., Chelmsford, MA) to 3.28 percent (+/- 0.63), as
determined in selected samples taken throughout each experiment. A value of 3.28% was
used for the calculation. The plasma density is 1.01 mgC/gL.
5.3 Results and discussion
5.3.1 Pilot study results
Figure 5.2 shows the pilot study results. Subcutaneous injection of 0.6 nCi 14C-
BCNU led to increase of the plasma 14C concentration, which seemed to reach a plateau
within 3 hours. This plasma 14C concentration of the rat with the activated device,
however, was not significantly higher than the background level throughout the 3-hour
measurement. The in vitro release studies in Chapter 4 showed incomplete of payload
release from devices packaged using the stainless steel frames and neoprene gaskets.
Besides, the packaged device was soaked in water for 2 days to test leakage before the
device implantation. The LSC data showed slightly higher than background values (- 50
DPM). But it was difficult to determine the exact amount of '4C-BCNU leaked because
the initial total loading was too low. All these were possible factors leading to the lower
plasma 14C level in the rat with the activated device than in the subcutaneous injected
control. Nevertheless, the injected control result was encouraging and clearly
demonstrated the high sensitivity of AMS with respect to low '4C detection. It was also
determined from this study that the suitable plasma sample size for AMS analysis was 25
iL as it showed the lease variation among repeated measurements.
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Figure 5.2 Plasma 14C concentration measured by AMS from a device activated in vivo and a
subcutaneous injected control. Both the activation and injection started at time zero. Each data
point represents means of 3-7 replicate measurements with 25 PL plasma sample.
5.3.2 In vivo release of 14C-BCNU
Six activations, each corresponding to the opening of one row of three or four
reservoirs with a total loading of 0.01 PCi 14C per row, were performed on three rats.
Five out of these six activations were successful with all of the membranes opened, as
confirmed by the optical microscopy observation of the explanted devices. The
unsuccessful activation was due to faulty wiring on a single row of one device. Figure 5.3
shows the temporal profile of in vivo BCNU release evaluated by AMS analysis of the
plasma 14C concentration of the blood samples from all successful activations. The
plasma 14C concentration remained at the background level following the unsuccessful
activation on one rat, as shown in the first segment in Figure 5.3a.
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Figure 5.3 Plasma 14C concentration measured by AMS from devices activated in vivo, with
three sequential activations in (a), two activations in (b), and one activation in (c). Plasma 14C
concentration from an unactivated device is plotted in each graph (empty circle labeled) as
controls. Each activation (denoted by the dashed line) corresponds to opening of one row of
reservoirs with 0.01 Ci loading. Each data point represents means of 3-7 replicate
measurements with 25 L plasma sample.
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All successful activations led to a sharp increase in the plasma 14C concentration
followed by a plateau, which is similar to both the in vitro (Figure 5.4) and injected
controls (Figure 5.5). The 14C level reached equilibrium almost instantaneously after each
activation for the in vitro controls. It took about half an hour to reach the plateau plasma
14C concentration for the injected control, and slightly longer for the rats with activated
devices.
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Figure 5.4 Cumulative 14C released from devices activated in vitro in saline. Each activation
(denoted by the dashed line) corresponds to opening of one row of reservoirs with 0.01 Ci
loading. Plot from the same data in Figure 4.10.
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Figure 5.5 Plasma 14C concentration measured by AMS from a subcutaneous
Each injection (denoted by the dashed line) corresponds to 0.014 LtCi loading.
represents means of 3-7 replicate measurements with 25 LL plasma sample.
injected control.
Each data point
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5.3.3 Discussion
The similarity in the shape of the 14C labeled BCNU release profiles between the
activated devices in vivo and both the in vitro and injected controls implies that the
pharmacokinetics dominated the release kinetics in all cases. The time to reach the
steady-state plasma 14C concentration was on the order of one hour. The diffusion of 14C
labeled BCNU from the activated devices in vivo also played a role by prolonging the
drug clearance time in the blood. Comparison of Figure 5.4 with Figure 5.3 shows that
the intrinsic release rate from an activated device in vitro was faster than the distribution
rate from an activated device in vivo. Clearly, the limiting resistance for in vivo
distribution is external to the device. Comparison of Figure 5.5 with Figure 5.3 shows
that more rapid distribution of BCNU occurred from the injected control than from
activated devices. The drug was diluted in saline solution just before injection, but was
mixed with the polyethylene glycol (PEG) gel in the reservoirs before activation. The
difference in the release rate between the activated MEMS device and the injected control
indicated that transport from a 50 m opening into surrounding tissue was intrinsically
slower than transport from a solution bolus delivered by injection.
It is also noted that the plasma 14C concentration of the injected control was about
three to five times higher than that of the rats with activated devices, even though the '4C
dosing of each injection was only 1.4 times the loading for each activation of the devices.
The main reason is the incomplete release of payload from stainless steel frame packaged
devices, as discussed in Chapter 4. The equilibrium plasma 14C concentration after the
first successful activations was about the same for two rats, but was nearly twice that
value for the other rat with an activated device. This interindividual variability is
probably due to the variability in the drug disposition between these animals, which may
be correlated with the low partition and hence the low bioavailability of the drug in
blood. Higher than tenfold interpatient variation in the blood level of BCNU has been
reported in the clinical study of high dose alkylators for the treatment of primary breast
cancer 1. Majority of the unreleased radioactivity was found to be trapped in the neoprene
gasket. Therefore, another possible reason for the different equilibrium plasma 4C level
was the different amount of radioactivity trapped in the neoprene gasket, although all
devices were packaged and filled in the same manner and in vitro release of two devices
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packaged in the same batch showed very little difference in the percentage of payload
release among the three activations (Figure 5.4).
BCNU has been known to degrade in aqueous media with a half-life of 10 to 20
minutes12. There appears to be two competing degradation mechanisms. It can be
enzymatically metabolized by the liver into an inactive form, or hydrolyzed in tissue to
an active alkylating agent 3' 14. BCNU has a relatively longer half-life in non-aqueous
media, with 74 days in 95% ethanol' 5. Both the PEG gel and 14C labeled BCNU were
dissolved in ethanol for injection into the devices to avoid decomposition of the drug
prior to release. Most of the measured 14C in plasma probably represented the
radioactivity carried by the degraded BCNU fragment, as proposed by DeVita'. This
could explain the rapid clearance of the plasma 14C level shown in Figure 5.3 and 5.5,
although BCNU is known to be a highly lypophilic compound.
The blood volume (BV) of rats can be estimated using 7% of body weight 16
(BW). The rats used in our study weighed in the range of 150-200 grams. Using a middle
value of 175 grams as the body weight, we can estimate the percentage of 14C distribution
in the blood:
Plasma t4C conc. x BV
'
4 C in blood % = C con. x BV (Equation 5.3)
'
4C injected
The plasma 14C concentration can be read from Figure 5.5 to be 45 fCi/giL. Using a blood
volume of 12.25 mL and 0.014 gtCi injected loading, the percentage of 14C that entered
the blood was approximately 4 %. This value agrees with the reported 1-5 % range in
literature1.
The plasma 14C concentration analysis gives acute release kinetics information
with high temporal resolution. Measuring the excreted 14C level is another approach to
obtain release kinetics information on a longer time scale and with more direct data
regarding mass balance.
5.4 Conclusions
The results of this study clearly demonstrate the feasibility of delivering BCNU
from this drug delivery MEMS device in vivo. Use of AMS made it possible to obtain
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accurate release kinetics of 14C-BCNU in vivo. The BCNU release kinetics information
also provides guidance for the tumor effect study presented in the next chapter.
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6 Tumor effect study
6.1 Introduction and motivation
One specific objective of this NIH project is to evaluate efficacy of drug release
from the MEMS device on a tumor model. We chose the tumor model because our
collaborator, Dr. Henry Brem at Johns Hopkins Medical Institutions (JHMI) has
pioneered local delivery of chemotherapeutic agents for treatment of malignant brain
tumors and his group has extensive experience in the preclinical efficacy evaluation of
various tumor models.
The efficacy evaluation of the drug delivery MEMS device on an experimental
tumor model has been designed in three phases. Phase I study is designed to ensure
proper device operation in vivo and to obtain BCNU dosage information necessary to
choose the proper operating space for the BCNU/IL-2 combination therapy. Phase II
study aims to develop dose-response curves for local delivery of combination BCNU/IL-
2 therapy, and to determine the drug delivery regimen that most effectively retards or
reverses growth of the tumor. Phase III study will evaluate the therapeutic regimen
established in Phase II study in a 180-day survival study in order to compare the relative
merit of the drug delivery MEMS technology with other existing technologies in
improving the animal survival against the tumor challenge.
This chapter describes two animal tests performed in collaboration with Dr. Henry
Brem's group at JHMI. The first test, though unsuccessful, presented the direction to
modify the device packaging and drug formulation so that the second test accomplished
the goal of Phase I study.
6.2 Experimental methods
6.2.1 Device fabrication and packaging
Devices (from Wafer # 070103-6) were fabricated using the same process
described in Chapter 2. The gold electrodes were patterned by wet etching of the
sputtered gold film.
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Different packaging methods were used in the two animal studies. Sixteen devices
in the first animal study were packaged using stainless steel frames with neoprene
gaskets. Each packaged device was filled with a total BCNU dosage of 0.6 mg distributed
evenly in 25 reservoirs. '4 C-BCNU was also filled into these reservoirs with a total
loading of 0.04 gCi for each device. Details about the packaging and chemical filling can
be found in Chapter 4.
Twenty-four devices in the second animal study were packaged using Pyrex
frames and plates, using the same method described in Chapter 4 except that the bonding
of the Pyrex chip to the Si device was achieved using anodic bonding instead of UV
epoxy bonding. This change arose from the observation that occasionally a few gold
membranes facing the reservoir opening became contaminated by the UV epoxy when
the Pyrex chip was pressed against the Si device, which could affect the membrane
opening. Detailed procedures of the anodic bonding can be found in Ho Duc's thesis'.
Bonding of the Pyrex-Pyrex parts was still made using the UV epoxy. Another difference
in the packaging is the absence of the top stainless steel frame from these devices in order
to avoid discomfort and pain to the animals caused by the thin (250 jpm thick) frame with
larger lateral dimension (11 x 11 mm) than the Pyrex chips (7.5 x 5.5 mm). Devices were
filled with mixture of 14C-BCNU (Moravek Biochemicals, Brea, CA), BCNU (Bristol-
Myers Squibb Co., Evansville, IN) and PEG (Mw 400) at 50:50 volume ratio between
BCNU and PEG. Three BCNU dosages (0.67 mg, 1.2 mg and 2 mg) were used to fill
these devices.
Both the stainless steel frame and Pyrex packaged devices used a blackened
platinum wire (approximately 6mm long) as an in vivo reference electrode. The wire was
soldered to the exposed end of one cable with epoxy covering the soldering joint.
Packaged devices were shipped overnight to JHMI on dry ice.
6.2.2 Animal protocol
The two animal tests used the same general procedure but different experimental
design in terms of number of animals, activation sequence, and controls, as described
below.
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6.2.2.1 General procedure
The tumor effect studies were performed in Dr. Henry Brem's group at JHMI.
The animal study protocol was approved by the Animal Care and Use Committee of
JHMI before implementation of any procedure.
Female rats (Fisher 344, weight 150-200 g) were purchased from Charles River.
Some rats were housed in normal cages; while others were housed individually in
metabolic cages (Nalgene model # 650-0100, Braintree Scientific Inc., Braintree, MA).
The metabolic cage features a unique funnel and cone design that effectively separates
feces and urine into tubes outside the cage. Animals were given standard rat chow and
water ad libitum at the JHMI Animal Facilities. Animals housed in metabolic cages were
given sugar water (4 tsp / 500 mL), which encouraged the animals to drink more and
allowed more frequent collection of urine samples. The urine tubes were rinsed clean
each time samples were taken. The metabolic cages were cleaned under flowing warm
tap water every three days.
Animals were anesthetized prior to all surgical procedures using an intra-
peritoneal injection of a stock solution containing ketamine hydrochloride (25 mg/mL),
xylazine (2.5 mg/mL), and 14.25% ethyl alcohol in normal saline. Post-operative
analgesics were given following every surgical procedure using a subcutaneous injection
of buprenorphine (0.1mg/kg). All operating procedures were performed using sterile
technique, with all instruments autoclaved and sterile gloves and masks worn throughout
the procedure.
The 9L glioma, an experimental gliosarcoma syngeneic to the F344 rat, was
maintained in the flank of a carrier rat. Each rat in the tumor effect study was implanted
with a 2 mm3 piece of 9L tumor from the carrier animal. Ten days after the tumor
implantation, the rats were randomized into different groups to receive different
treatment.
Sterilized devices were implanted subcutaneously next to the established tumor
with the electrodes facing the tumor and the cable exiting through the incision. The
incision was closed with autoclips. Animals were re-anesthetized on scheduled days for
activation. Their original incision was prepped and opened to allow electrical connection
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to the potentiostat. Following activation, the cable was cut flush at the end and returned
to the subcutaneous pocket and the incision was closed with autoclips.
Tumor growth was evaluated using calipers three times a week and the tumor
volume calculated using approximation of an ellipsoid:
Vumor = Length x Width x Height x 6 (Equation 6.1)
Animals were checked daily for physical or behavioral evidence of toxicity, such
as decreased alertness, impaired grooming, or gait disturbances. If any deficits developed,
the animals would be euthanized by CO2 inhalation and all organs removed for
histological examination. The end point of the Phase I efficacy study was set at 22 days
post tumor implantation. Animals were euthanized after experiments were completed by
either CO 2 inhalation or a sodium pentobarbital overdose (200 mg/kg, to effect). Devices
were explanted and shipped to MIT for optical microscopy inspection (Olympus BH-2).
Device activation was performed using the same protocol for the in vivo 1 4C-
BCNU release kinetics study in Chapter 5, which included four cathodic cleaning cycles
from -1.0 to -1.5 V, four diagnostic scan cycles from 0 to 1.8 V, and 10-minute square
wave voltammetry between 0 and 1.2 V, all relative to the blackened Pt wire reference
electrode.
Excreted radioactivity from each rat housed individually in metabolic cages was
analyzed to correlate with the tumor size measurement. Only urine samples were taken
after an initial trial showed no radioactivity recovered in fecal samples. A 1 mL urine
sample was mixed with 5 mL scintillation fluid (Ready Gel, Beckman Coulter Inc.,
Fullerton, CA) in a 7 mL scintillation vial and measured on a liquid scintillation counter
(Beckman Coulter Inc., Fullerton, CA). A counting efficiency of 0.91 was used to convert
the output data from counts per minute (CPM) to disintegrations per minute (DPM),
which was then converted to radioactivity by a conversion factor of 2.2 x 106 DPM/jiCi.
6.2.2.2 First tumor effect study
Twenty-four rats were divided into 5 groups 10 days after the tumor implantation
that received different treatment, as described in Table 6.1. Controls for this study
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included 4 rats with unactivated devices, 2 rats with empty devices, and 6 rats with no
treatment.
Table 6.1 Animal grouping and device activation sequence for the first tumor effect study.
Rat # Device # Activation sequence Notes
RI-R6 Al-Al 1 activation of full dose on Rats housed in
3/9/04 metabolic cages
R7-R12 A7-A12 1 activation of 2/5 dose on Rats housed in
3/9/04, 1 activation of 3/5 dose metabolic cages
on 3/15/04
R13-R16 U1-U4 1 activation of half dose on Rats housed in
7/1/04, 1 activation of another metabolic cages
half dose on 7/6/04
R17-R18 El-E2 No activation Empty chip control
R19-R24 N/A N/A No treatment control
6.2.2.3 Second tumor effect study
Forty-eight rats were divided into 8 groups 10 days after the tumor implantation
that received different treatment, as described in Table 6.2. Controls for this study
included 6 rats with unactivated devices, 3 groups of 18 rats with subcutaneously injected
BCNU, and 6 rats with no treatment. Due to the limited number of metabolic cages
available at the time of this study, 3 rats in each group were housed in metabolic cages
for collection of urine samples for 14C analysis, and the other 3 rats from each group were
housed in normal cages. The tumor growth of all rats was monitored using a caliper.
The same BCNU/PEG mixture (at 50:50 volume ratio) that was used to fill the
devices was used for the injection groups. Because of the difficulty in precisely
controlling the injected volume manually using a 10 gL syringe, the actual dosage that
the injected control rats received was higher than the target value. The actual amount of
the injected dosage was estimated by comparing the scintillation counting data of the
manually injected volume to that using a micropump.
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Table 6.2 Animal grouping and device activation sequence for the second tumor effect study.
Rat # Device # Activation sequence Notes
R1-R6 A-l-A1-6 1 activation of halfdose on Metabolic cages used for
(0.67 mg 7/1/04, 1 activation of another Rats R1 - R3
BCNU) half dose on 7/6/04
R7-R12 A2-1-A2-6 1 activation of half dose on Metabolic cages used for
(1.2 mg 7/1/04, 1 activation of another Rats R7 - R9
BCNU) half dose on 7/6/04
R13-R18 A3-1-A3-6 1 activation of half dose on Metabolic cages used for
(2 mg 7/1/04, 1 activation of another Rats R13 - R15
BCNU) half dose on 7/6/04
R19-R24 UI-1-U1-6 No activation Metabolic cages used for
(2 mg Rats R19 - R21
BCNU)
R25-R30 0.67mg 1 injection of half dose on Metabolic cages used for
(1.4 mg) 7/1/04, 1 injection of another Rats R25 - R27
BCNU* half dose on 7/6/04
R31-R36 1.3 mg 1 injection of half dose on Metabolic cages used for
(1.5 mg) 7/1/04, 1 injection of another Rats R31 - R33
BCNU* half dose on 7/6/04
R37-R42 2 mg 1 injection of half dose on Metabolic cages used for
(2mg) 7/1/04, 1 injection of another Rats R37 - R39
BCNU* dose on 7/6/04
R43-R48 N/A N/A No treatment control
*: The numbers before the parenthesis indicate the target BCNU dosage, and the numbers in
parenthesis indicate the actual dosage that the injected control rats received.
6.3 Results and discussion
6.3.1 First tumor effect study
Figure 6.1 shows the tumor growth over time for the different treatment groups.
No statistical difference was observed in the tumor size between rats with activated
devices and unactivated controls or No treatment controls.
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Figure 6.1 Tumor growth measurement for different treatment groups in the first tumor effect
study.
The above tumor growth results could be correlated with the cumulative
percentage of urinary 14C recovery data shown in Figure 6.2. Optical microscopy
examination on the explanted devices showed that 10 out of the 12 activated devices had
more than 85% of the membranes fully opened. The other 2 devices had about 25%
membrane opening rate, probably because of faulty wiring and/or insufficient fluid
around the devices in vivo. The cumulative 14C-BCNU excreted from the urine, however,
was only a small portion (5-11%) of the total loading for all the activated devices. Our
previous study showed about 60% urinary recovery of 14C from a subcutaneously injected
dose of 14C-BCNU in the rat flank.
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Figure 6.2 Cumulative percentage of 14C excreted from urine in rats with (a) devices with 25
membranes activated on Day 10 and (b) devices with 10 membranes activated on Day 10 and 15
membranes on Day 16. Each device loaded with 0.04 gCi 14C-BCNU and 0.6 mg BCNU.
Two in vivo activated devices were dissembled. Scintillation counting on the
individual components soaked in deionized water overnight indicated a large amount of
'
4C retained in the neoprene gasket (approximately 25%). About 5% radioactivity was
also recovered from the packaging frames. Moreover, the in vitro BCNU release test also
showed a very low percentage of payload release from devices filled with pure BCNU,
but higher percentage of payload release with addition of polyethylene glycol (see Figure
4.10). All these results motivated the design of a Pyrex package and the investigation of
drug formulation effect on BCNU release kinetics, as discussed in Chapter 4.
6.3.2 Second tumor effect study
The tumor growth over time in the second tumor effect study is shown in Figure
3. A noticeable difference between Figure 6.3 and Figure 6.1 is the much slower tumor
growth in the rats that received activated devices or subcutaneous BCNU injections than
the unactivated or No treatment control groups in the second study. Both the activated
groups and injected control groups showed dose related retarding effect on the tumor
growth; that is, the higher the BCNU dosage delivered, the slower the tumor growth. It is
also interesting to note comparable tumor size between the activated groups and injected
control groups with the same BCNU dosage.
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Figure 6.3 Tumor growth measurement for different treatment groups in the second tumor effect
study. Each data point represents mean ± SD of measurements from 6 rats.
Figure 6.4 shows the cumulative percentage of 14C excreted from the 3 rats
housed in metabolic cages in each of the 3 groups that received activated devices. Optical
microscopy examination of the explanted devices showed that all the activated devices
had more than 80 % of the membranes fully opened except one device filled with 1.2 mg
BCNU dosage. This device had all the membranes on top of the one macroreservoir
opened, but none of the membranes on top of the other macroreservoir opened, or even
showed any sign of corrosion. Optical microscopy did not show broken wire bonds on
this device. A most probable explanation for the uncorroded membranes on this device
could be that the membranes that were already activated in the first activation were
activated again in the second activation by mistake. All urine counting and tumor
measurement data from this device were excluded from further analysis. The urinary
recovery of 14C for all other devices after two activations was 51 ± 12 % of the initial
loading.
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Figure 6.4 Cumulative percentage of 14C excreted from rats with devices activated in vivo filled
with different BCNU dosage (a) 0.67 mg, (b) 1.2 mg and (c) 2 mg. Dashed lines indicated time of
activations to release half of the filled dosage.
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The first device activation led to a sharp increase in the excreted 14C level, which
seemed to be cleared from urine within 1 day. The magnitude of increase in the urinary
14C level after the second activation was much smaller than after the first activation for
majority of the rats housed in metabolic cages with activated devices. The 3 devices with
high BCNU dosage leaked only one day after implantation (Figure 6.4c). The 3
unactivated control devices also showed leakage of 14C within 3 to 5 days after
implantation (Figure 6.5).
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Figure 6.5 Cumulative percentage of 14C excreted from rats with unactivated devices filled with 2
mg BCNU dosage.
The cumulative 14C release profiles of the injected control groups showed two
clear plateaus within 1 day after the injection (see Figure 6.6). The urinary recovery of
14C was 57 + 13 % of the total injected loading.
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Figure 6.6 Cumulative percentage of 14C excreted from subcutaneously injected control groups
with BCNU dosages of (a) 1.4 mg (b) 1.5 mg and (c) 2 mg.
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6.3.3 Discussion
Results from the second tumor effect study successfully demonstrated the efficacy
of BCNU released from the drug delivery device on the 9L rat flank tumor model. This
success comes from improvement in the device packaging and drug formulation over the
first unsuccessful tumor effect study. The Pyrex package effectively enhanced the device
capacity without increasing the overall package dimension. Co-formulation of PEG with
BCNU led to complete and rapid release of drug in vivo, as supported by the closeness in
the urinary 14C level and clearance time between the activated device groups and the
injected control groups.
Rats with activated devices showed comparable tumor growth data to rats with
subcutaneous injections, indicating that the device packaging, shipping and gold
membrane corrosion processes did not seem to affect the therapeutic effect of BCNU
delivered from the activated devices. The antitumor activity of BCNU arises from its
alkylating decomposition products that induce DNA crosslinking and kill cells2. Sealing
of the MEMS device after BCNU filling was made by 20-second UV exposure. A
colorimetric assay3 (conducted by Helen Tsai and Grace Kim) has shown very similar
slope of the standardization curves from BCNU samples with and without 1-minute UV
exposure, suggesting that the UV exposure did not change the activity of the drug. It is
unclear whether the corrosion process had an effect on the decomposition of BCNU
contained inside the reservoirs. Nevertheless, BCNU delivered from the activated drug
delivery device seemed to exhibit similar antitumor activity to BCNU directly delivered
from injection. On the other hand, this conclusion may not be applicable to other
therapeutic agents delivered from the drug delivery device. Appropriate in vitro assays
will be necessary to evaluate the influence of filling methods and device activation on the
drug activity and to ensure that the drugs remain active prior to release.
It is interesting to compare the tumor growth data from this study with those using
other BCNU local delivery technologies. Figure 6.7 shows the tumor volume 22 days
post tumor implantation for rats implanted with the MEMS device, with the GLIADEL®
wafer (a polyanhydride based copolymer wafer with BCNU distributed uniformly in the
wafer4), and with the polymer chip (a resorbable polymeric device with rows of drug
containing reservoirs each covered by a biodegradable polymer5) at different BCNU
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dosages. The data at zero BCNU dosage correspond to results from no chip/wafer control
groups. The variation in the tumor volume of these control groups makes it difficult to
conclude if there was statistically significant difference in the efficacy between the
pulsatile release from the MEMS device and the sustained release from the polymer
systems on this flank tumor model. Sustained delivery of BCNU from both the
GLIDEL® wafer and poly (L-lactide co-glycolide) (PLG) microspheres have been shown
to be statistically more effective than the equipotent bolus injection of BCNU to enhance
survival in rat glioma models 6-8 . Further study is needed to directly evaluate the efficacy
of the MEMS device comparing to the polymer systems against the 9L tumor model. On
the other hand, sustained delivery of BCNU can also be achieved using the MEMS
device simply by sequential superposition of the pulsatile profiles from many individual
reservoirs.
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Figure 6.7 Tumor volume measured 22 days after tumor implantation in the rat flank using
different delivery vehicles.
Some devices showed unexpectedly earlier leakage of payload in vivo (3-5 days
after device implantation) comparing to the in vitro leak test result (zero leakage up to 12
days). A possible reason could be the damage of gold membranes due to the direct
contact of the device top surface with the animal tissue. Optical microscopy examination
on the explanted devices showed at least one broken anode gold membrane on 5 out of
the 6 unactivated devices. About one third of all the explanted devices (including both the
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activated and the unactivated devices) had broken membranes on the cathode too.
Therefore, it is proposed that a protective frame be added on top of the device packaging
in order to prevent the premature drug leakage due to broken gold membranes in future in
vivo studies.
It is also noted that despite the leakage of the unactivated devices, the tumor
growth of this group was hardly inhibited comparing to the activated and No treatment
control groups. It was observed at the time of the first activation that the cable attached to
the device was too long, which displaced the Si device from the tumor site by about 10
mm. The device was pulled back with the electrode surface facing the tumor before the
activation. After activation, the cable was cut short to ensure close contact of the device
with the tumor after the incision was closed. No action was taken to the rats with
unactivated devices. It is suspected that majority of the leaked drug from the unactivated
devices was not able to diffuse to the tumor site to inhibit its growth.
6.4 Conclusions
BCNU delivered from the MEMS device has shown efficacy against the growth
of a 9L flank tumor in rats. Co-formulation of BCNU with PEG led to complete and rapid
release of drug in vivo. The retarding effect of BCNU on the tumor growth was dose
dependent in the range of 0.67 - 2 mg investigated in this chapter. BCNU delivered from
activated devices seemed to be as effective as equipotent injections of BCNU in retarding
the tumor growth. These results provide important BCNU dosage information for the
second phase efficacy study. The drug leakage problem discovered from the in vivo study
should be addressed before the next efficacy study. It may also be necessary to test
leakage of any proposed new packaging method in vivo to ensure that the leakage
problem is indeed solved.
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7 Conclusions and future study
7.1 Summary of results
This thesis presents an in-depth study on the mechanical integrity of gold
membranes on the drug delivery MEMS device. The in vivo operation of the device has
been evaluated using a chemotherapeutic agent against a flank tumor model.
A bulge test apparatus was constructed to pressurize the gold membrane from
underneath and to measure the membrane deflection using optical interferometry. Fitting
the deflection and pressure data to an available bulge equation allowed extraction of the
elastic modulus and residual stress of the gold membrane. Different processing conditions
led to different gold membrane microstructure and mechanical properties. The bulge test
was also used combined with an in situ observation setup to study the electrochemical
disintegration process of the gold membranes in chloride containing solutions. A gradual
loss of the membrane mechanical integrity was observed with progression of corrosion.
The gold membrane disintegration probably occurred by a combination of membrane
thinning through active dissolution and accumulation of plastic deformation due to the
transient formation of a passive film on top of the gold membrane.
In vivo release of a chemotherapeutic agent, BCNU, from the drug delivery device
was demonstrated in a rat flank model. Acute temporal release kinetics of 14 C-BCNU in
vivo was evaluated by analysis of the plasma 14C concentration using the accelerator mass
spectrometry (AMS) technique. Furthermore, BCNU delivered from the drug delivery
device showed a dose dependent retarding effect on the growth of a 9L flank tumor
model in rats.
The mechanical characterization studies presented in this thesis provided a deeper
understanding of the materials science issues related with the drug delivery device so that
the device yield and quality could be improved through optimized processing conditions.
Obtaining high quality devices was critical to the success of evaluating their in vivo
operation. The in vivo studies provided preliminary efficacy validation of the drug
delivery device as well as important dosage information for further efficacy evaluation.
All these results also provided guidance for further improvement and more
comprehensive evaluation of the device operation in vivo.
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7.2 Future work
7.2.1 Dielectric coating for long term implantation and operation
This thesis has focused on the processing optimization of the gold membranes on
the drug delivery device. Another component that may need further processing
optimization for reliable long term operation is the dielectric passivation coating that is
patterned on the device surface to protect part of the gold electrode (traces) from
unwanted corrosion.
Key requirements for the dielectric coating include biocompatibility, stability and
hermeticity. The current MEMS device uses silicon dioxide (SiO2) grown by plasma
enhanced chemical vapor deposition (PECVD) as the passivation layer. In vivo test of this
material using the cage implant system has shown good biocompatibility and superior
biofouling reduction compared to unmodified silicon'. However, long term (up to 6
months) in vivo studies showed a significant detachment and dissolution of SiO2 within
two months post-implantation 2. There is also literature reporting the dissolution of SiO2
films from retinal implants after subretinal implantation in rabbits for 6-12 months3 .
Other materials, such as silicon nitride (SiNx, x here denoting nonstoichiometric
nitride) or amorphous silicon carbide4 (a-SiC:H) can be explored to replace SiO2 as the
dielectric coating suitable for long term implantation and operation of the MEMS device.
Adhesion of the dielectric coating to the gold is critical to ensuring long term stability of
the coating. The "Scotch tape test" provides a quick qualitative evaluation of the adhesion
property of the coating5. Chronic soaking tests can be performed to measure the coating
dissolution rate in PBS. Candidates that show superior properties in the above in vitro
tests will be further evaluated for long term biocompatibility and stability in vivo.
7.2.2 Improvement of membrane opening reliability in vivo
Current drug delivery devices use electrochemical corrosion to open the gold
membranes for drug release. Results from Chapter 3 showed that the non-uniform nature
of the corrosion process led to scatter in the time needed to open a membrane, and that
1 0-minute square wave voltammetry was sufficient to achieve 100% opening of all the
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membranes on one device in vitro. However, results from Chapter 5 and Chapter 6
showed approximately 85 % success of membrane opening in vivo. Possible reasons for
the failure in membrane opening may include wrong wiring, insufficient body fluid,
breakdown of electric path due to scratch on the dielectric coating along the trace, or
adhesion of proteins or other molecules on the gold surface. It is important to address
these problems in order to achieve failsafe operation of the device in vivo.
Results from Chapter 3 showed that blackening the platinum reference electrode
improved the reproducibility of the cyclic electrochemical results. The blackening
approach can also be applied to the gold membranes for more reproducible opening.
Christopher Puleo and Nolan Flynn have developed an electrodeposition process to
blacken the anode gold membranes. Further study is needed to test whether this
procedure has the intended effect to improve the reproducibility of membrane opening in
vivo. Device with blackened gold membranes should also be tested for leakage to ensure
that the blackening procedure does not compromise the integrity of the gold membranes.
Another possible area of improvement is the voltammetry parameters for activating the
gold membranes, including the time and potential range of the cathodic cleaning stage,
and the potential range, duty cycle and frequency of the square wave voltammetry.
Further investigation of the plastic deformation of the corroded gold membranes may
provide useful guidance in the optimization of activation parameters.
An alternative approach is to adopt a fuse activation mechanism that uses resistive
heating to melt the membranes. One obvious advantage of the fuse activation mechanism
is that it does not need the presence of chloride ions for the membrane activation, and
thus is expected to exhibit higher operation reproducibility than the electrochemical
activation mechanism. Hong Linh Ho Duc has successfully demonstrated this mechanism
in vitro on devices with modified electrode design. Further study will focus on
optimization of the membrane materials, evaluation of the biological response of this
mechanism, and in vivo evaluation of the device operation reliability.
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7.2.3 Delivery of IL-2/BCNU combination therapy to the tumor model
Interleukin-2 (IL-2) is a cytokine that exerts a number of immunomodulatory
activities in a paracrine fashion, including enhancement of the T cell growth, T cell
activation, cytotoxic T lymphocyte growth and natural killer cell activation6 ' 7. Local
delivery of IL-2, either by genetically engineered tumor cells or by gelatin/chondroitin
sulphate polymer microspheres, in combination with the local delivery of BCNU from
biodegradable polymers, has recently been shown to achieve synergistic efficacy in
various animal tumor models8 ' 9. Precise control of the delivery timing and dosage of IL-2
and BCNU is critical to achieving optimal efficacy, which is nevertheless difficult to
achieve using the available polymer wafer system. Therefore, the IL-2/BCNU
combination therapy provides a suitable experimental paradigm for evaluating the
efficacy of the drug delivery MEMS device.
Further efficacy evaluation of delivering the IL-2/BCNU combination therapy
from the drug delivery device on the 9L flank tumor model will be conducted based on
the Phase I study completed in this thesis. IL-2 is a protein drug. It is important that IL-2
retain its activity during the filling, sealing and other handling processes. Studies are
currently being carried out by Grace Kim to develop in vitro IL-2 activity assays so that
the influence of drug formulation, device packaging and activation on the IL-2 contained
in the reservoirs can be evaluated. A series of dose ranging studies, using similar
protocols as in the Phase I study, will be conducted to establish the optimal IL-2 and
BCNU dosages and delivery sequence that most effectively retards the tumor growth. In
vivo release profiles of radiolabeled IL-2/BCNU combination will also be evaluated to
correlate with the tumor effect study results. The capacity of the current Pyrex packaged
device is expected to be sufficient to contain therapeutic amounts of IL-2 and BCNU.
However, the Pyrex chip design may need to be modified to contain more compartments
and hence allow more impendent release events from one device.
The optimized treatment regimen established from the dose ranging study will be
evaluated in the Phase III survival study with 180-day duration. Results will be compared
with currently available therapies using the BCNU polymer wafer, the IL-2 microspheres,
or their combination to evaluate the relative merit of the drug delivery MEMS technology
against the challenge of the 9L flank tumor model.
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7.2.4 Exploration of other applications
The tumor model is a suitable experimental paradigm for evaluating the efficacy
of the drug delivery MEMS device with promises of leading to useful clinical
applications. This device has also been used to locally deliver an antioxidant drug as
inducers for gene regulation in a nude mouse model. Both in vitro and in vivo studies
have shown successful induction evaluated by the luciferase assay. Further study will
investigate the delivery of both the gene coded virus and inducer from one device in vivo.
At the same time, this device can be used to deliver a wide array of other therapeutic
agents that capitalize on the unique capability of the device to locally deliver multiple
substances with precise control of the dosages and temporal profiles. An even broader
perspective, however, is to envision the MEMS technology, the key design principle of
this drug delivery device, as a uniquely powerful platform for improved physiological
integration of the chemical or physical stimuli with the delicate systems of the human
body than is currently available in clinical or commercial treatments' ° .
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